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Tetherin/BST2 is an interferon-inducible antiviral factor that restricts the egress of 
numerous enveloped viruses including HIV-1. Consequently, many viruses have evolved 
mechanisms to actively or passively evade restriction by tetherin. Most studies conducted 
to date focused on the tetherin-evasion mechanism of complex retroviruses like HIV and 
SIV, which encode accessory proteins like Vpu and Nef respectively to counteract 
tetherin-mediated restriction. However, there is a wide gap in knowledge in 
understanding how simple retroviruses (that includes alpharetroviruses, some 
betaretroviruses and gammaretroviruses) that lack obvious accessory proteins like HIV-1 
Vpu and SIV-Nef, evade restriction by tetherin.  
In this dissertation, I have established that Simian retrovirus type-3, a prototypical 
type-D betaretrovirus, isolated from Asian macaques, is restricted by human tetherin but 
not by rhesus macaque tetherin. This differential sensitivity indicated that SRV-3 has a 
mechanism to evade tetherin-mediated restriction. I have identified the SRV-3 envelope 
(Env) glycoprotein as the viral determinant of tetherin antagonism, and have also found 
that SRV-3 envelope expression in-trans was sufficient to rescue a heterologous virus 
from tetherin. SRV-3 Env resulted in cell-surface down-modulation of rhesus tetherin, 
and this mechanism of tetherin-antagonism is independent of the SRV-3 Env trafficking 
pathway. The target specificity of SRV-3 Env overlapped a stretch of five residues 
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(G14DIWK18) in the rhesus tetherin cytoplasmic tail that are absent from human tetherin. 
Additionally, I was able to show that SRV-3 Env physically interacts with rhesus tetherin 
by targeting the G14DIWK18 motif. 
SRV-3 belongs to a large supergroup of retroviruses, called the RDR Interference 
Supergroup. Due to this reason, I screened additional RDR envelope glycoproteins for 
their ability to antagonize a panel of tetherin homologs. All the RDR envelopes tested 
were sensitive to human tetherin but exhibited anti-tetherin activity when tested against a 
panel of tetherin homologs from squirrel monkey, baboon, dog and cat.  
I also found that several non-RDR gammaretroviral envelope glycoproteins also 
have anti-tetherin function. Thus, tetherin-antagonism is not just restricted to the 
envelope glycoproteins of retroviruses in the RDR interference supergroups but extends 
to other non-RDR gammaretroviruses as well. To my knowledge, this is the first 
characterization of gamma-type envelopes as tetherin antagonists. Thus, in the absence of 
a dedicated tetherin antagonist, many simple retroviruses in the beta- and 
gammaretrovirus genera may evade tetherin-mediated restriction through neo-
functionalization of their envelope glycoproteins. We speculate that the evolutionary 
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Retroviruses are highly pathogenic enveloped viruses that have single-stranded 
positive-sense RNA genomes. These viruses have been isolated from diverse vertebrate 
hosts, including fishes, birds, reptiles and mammals.1 The most distinguishing feature of a 
retrovirus is the presence of the enzyme viral reverse transcriptase (RT), that converts the 
viral RNA genome into double-stranded DNA.2 This viral DNA gets irreversibly 
integrated into the host cell genome by the viral integrase (IN) to form a DNA provirus.2  
A mature retrovirus ranges between 80nm-100nm in diameter and is enclosed by 
the host cell-derived lipid bilayer.2 The retrovirus consists of a dimeric positive-sense 
RNA genome that has a 5’ cap and a long poly (A) tail at its 3’ end.3 The viral RNA 
genome is flanked by a short-repeated region (R) on either side. A unique 5’ sequence 
(U5) important for proviral integration is situated downstream of the 5’ R region. The 
primer binding site (pbs) is located right after the U5 region.4 Another unique 3’ 
sequence (U3) is situated downstream of the retroviral genes. The U3 sequence is 
preceded by a short polypurine tract (ppt). The ppt serves as the initiation site for the 
synthesis of the DNA sense strand.4 A quintessential retroviral genome consists of four 
genes namely gag, pro, pol, and env.4 The gag encodes the viral structural proteins: 
matrix (MA), capsid (CA) and nucleocapsid (NC). The pro and pol genes encode the 
viral enzymes: protease (PR), integrase (IN) and reverse transcriptase (RT). The env gene 
encodes an envelope glycoprotein (Env) that is characterized by a surface subunit (SU) 
and a transmembrane subunit (TM). The SU and the TM subunits oligomerizes to form 
heterotrimers that appear as spikes embedded in the lipid bilayer envelope (Figure 1.1A). 
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The functions of the different viral proteins in the retroviral life cycle are summarized in 
table 1.1. 
Retroviruses are often referred to as simple or complex on the basis of the 
presence or absence of accessory genes. Alpharetroviruses, gammaretroviruses and some 
betaretroviruses encode the four essential retroviral genes (gag, pro, pol and env), and 
lack accessory genes; hence, are termed as simple retroviruses (Figure 1.1B). 
Lentiviruses, deltaretroviruses, epsilonretroviruses and spumaviruses are called complex 
retroviruses as they have additional accessory genes in their genomes (Figure 1.1B).  
Depending on the mode of transmission, retroviruses are also classified as 
exogenous or endogenous retroviruses. Retroviruses that are horizontally transmitted 
from one individual to another are known as exogenous retroviruses. Occasionally, a 
retrovirus infects a germ line cell and randomly integrates its genome into the host 
genome to form a provirus that may persist and get vertically transmitted from parent to 
offspring. Such a retroviral insertion is called endogenous retrovirus.5 Majority of the 
retroviruses are well-known for their pathogenicity, but some of them also serve as 

















Figure 1.1. Retrovirus virion and genomes. (A) Schematic showing the structure of a 
mature retrovirus. The matured virion is surrounded by a lipid bilayer (dark blue) derived 
from the host cell. The envelope heterotrimers are embedded in the lipid bilayer (orange). 
The matrix protein (MA; shown in purple) is situated underneath the lipid bilayer. The 
dimeric viral RNA genome and the viral enzymes reverse transcriptase (RT; light blue), 
protease (PR; yellow) and integrase (IN; pink) are enclosed within the capsid core (CA; 
grey). (B) Schematic showing the genomic organization of retrovirus. Cartoons showing 
the DNA proviruses from the simple retrovirus (MPMV/SRV-3) and complex retrovirus 
(HIV-1). MPMV has a simple genomic organization consisting of the gag (green), pro 
(blue), pol (light blue) and env (orange) genes. In contrast, the HIV-1 has a more complex 
genomic organization. Apart from the gag (green), pol (light blue; pro and pol are 
expressed from the same reading frame) and env (orange) genes, HIV-1 has two 
regulatory genes, tat and rev (gray) and accessory genes like vif, vpu and nef (dark pink). 
The long terminal repeats (LTRs) are shown on either side of the genomes. The LTRs 
have regulatory functions. 
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Table 1.1. The functional significance of the retroviral proteins. 
 
Viral Proteins                               Function 
Matrix (MA) Structural protein encoded by gag; helps in the assembly 
of retroviral particles at the plasma membrane.2 
Capsid (CA) Structural protein encoded by gag; forms a protective 
shell surrounding the inner viral core.2 
Nucleocapsid (NC) Structural protein encoded by gag; binds to the viral 
RNA and promotes viral genome packaging.2 
Protease (PR) Viral enzyme; promotes viral maturation by cleaving the 
Gag and Gag-Pol polyproteins into their respective viral 
proteins.2 
Reverse Transcriptase (RT) Viral enzyme; reverse transcribes the viral RNA genome 
into a ds-DNA.2 
Integrase (IN) Viral enzyme; favors integration of the viral DNA into 
the host genome.2 
Surface subunit (SU) Envelope glycoprotein subunit; recognizes and binds to 
the receptor on the host cell surface.2 
Transmembrane subunit (TM)  Envelope glycoprotein subunit; mediates fusion with the 
host cell membrane and facilitates viral entry.2  










1.2 Life cycle of retrovirus 
The retroviruses perpetuate through an extraordinary life cycle that involves 
reverse transcription and provirus formation.  The entry of the retrovirus within the host 
cell is mediated by the recognition and the binding of the host cell receptor by the surface 
subunit of the viral envelope glycoprotein.2 Different genera of retroviruses use different 
receptors for viral entry. For instance, HIV-1 uses an immunoglobin-like molecule called 
CD4 as a receptor and a co-receptor called CXCR4 or CCR5.7 The gammaretroviruses 
use solute transporters with multiple transmembrane domains as receptors.8 Upon binding 
to the host cell receptor, both the SU and TM undergo conformational changes which 
facilitate fusion with the host cell membrane. The fusion event leads to the release and 
uncoating of the viral capsid core in order to deliver the viral RNA genome and the viral 
proteins into the host cell cytoplasm. The viral RNA is reverse transcribed into double-
stranded (ds) DNA in the cytoplasm. The viral DNA together with the cellular and the 
viral proteins forms the pre-integration complex (PIC). The PIC is imported into the 
nucleus, and the viral DNA is integrated randomly within the host genome leading to the 
formation of a DNA provirus.  
The viral DNA is transcribed into unspliced, singly-spliced and multiple spliced 
mRNA transcripts that are exported out of the nucleus. The unspliced mRNAs form the 
viral genomic RNA and also encode the viral Gag and Gag-Pol precursor polyproteins in 
the cell cytoplasm. The unspliced mRNAs of type-D retroviruses contain cis-acting 
elements called the constitutive transport elements (CTEs).9 The CTEs facilitate the 
nuclear export of unspliced mRNA transcripts. In complex retroviruses like HIV-1, 
nuclear export of unspliced mRNA is carried out by the regulator of expression of virion 
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(REV) protein.4 The singly-spliced mRNA encodes the envelope glycoprotein (Env) in 
simple retroviruses whereas alternatively spliced mRNAs encode the Env and accessory 
proteins in complex retroviruses.4 Unlike the Gag and Gag-Pol polyproteins, the envelope 
proteins are synthesized in the rough endoplasmic reticulum (RER) and are transported to 
the plasma membrane via the trans-Golgi network.  
Most retroviruses assemble at the plasma membrane with the exceptions of beta- 
and spumaretroviruses that assemble in the cell cytoplasm.4 Following assembly, the 
retroviral particle buds out from the host cell membrane and is released. During this step, 
the immature retroviral particle acquires the lipid bilayer envelope from the host cell. 
Eventually, the viral protease cleaves the Gag and the Gag-Pol precursor polyproteins 
into their respective proteins to produce a mature infectious virion. The different stages in 


















Figure 1.2. Schematic illustrating the life cycle of a retrovirus. The retroviral life 
cycle consists of the following steps: receptor binding, membrane fusion, uncoating, 
reverse transcription of viral RNA to ds-DNA, nuclear import and integration of pre-
integration complex to form a provirus, transcription of the viral DNA, nuclear export 











1.3 Taxonomic classification of retrovirus 
The family Retroviridae is classified into two subfamilies: the Orthoretrovirinae 
and the Spumaretrovirinae.4 The Orthoretrovirinae consists of six genera: 
alpharetrovirus, betaretrovirus, gammaretrovirus, deltaretrovirus, epsilonretrovirus and 
lentivirus.4 The Spumaretrovirinae consists of a single genus, spumavirus.4 A 
phylogenetic relationship among the retroviruses of the different genera of the 
Orthoretrovirinae and the Spumaretrovirinae subfamilies are shown in Figure 1.3. The 
distinguishing features of the retroviruses belonging to the different genera are briefly 
discussed below and are summarized in Table 1.2. 
 
1.3.1 Subfamily: Orthoretrovirinae 
1.3.1.1 Genus: Alpharetrovirus 
As discussed in section 1.1, alpharetroviruses are considered as simple 
retroviruses since their genomes contains ORFs for only four genes: gag, pro, pol and 
env. Presence of any accessory genes has not yet been reported. The alpharetroviruses 
exhibit a ‘C-type’ morphology meaning that they all have round and centrally located 
nucleocapsid cores.2 The viral assembly takes place at the plasma membrane.10 This 
genus consists of both oncogenic and non-oncogenic exogenous and endogenous 
retroviruses of avian species. Two well-known examples of alpharetroviruses are the 
Rous sarcoma virus and Avian Leukosis virus. Rous sarcoma virus was first identified as 
an oncovirus by Peyton Rous in 1911. This discovery was very significant as it opened 
the gateway to the discovery of numerous other retroviruses.  
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1.3.1.2 Genus: Betaretrovirus 
Like alpharetroviruses, betaretroviruses include both simple exogenous and 
endogenous retroviruses exhibiting an eccentric and spherical (‘B-type’ morphology) or a 
cylindrical nucleocapsid core (‘D-type’ morphology).10 These retroviruses assemble their 
Gag proteins into immature capsid-like particles in the cytoplasm that are transported to 
the plasma membrane for budding and release.10 The betaretroviral genome consists of 
gag, pro, pol and env genes, all of which are in different reading frames (Figure 1.1B).10  
The type-B betaretroviruses are characterized by a beta-type envelope TM subunit 
whereas the type-D retroviruses are regarded as recombinant betaretroviruses because 
their envelope glycoproteins consist of gamma-type TM subunits and resemble the 
envelope glycoprotein of a typical gammaretrovirus.11 The different types of retroviral 
envelopes are discussed in details in section 1.4. Evidence suggests that the type-D 
retroviruses originated as a result of a recombination between an ancient virus containing 
beta-like viral gag and pol genes, and an ancient virus containing a gamma-like viral env 
gene.11 As such, the type-D retroviruses share a high degree of sequence homology in 
their Gag and Pol proteins with the betaretroviruses but their env gene resembles that of 
gammaretroviruses.12 The type-D retroviruses consist of eight serotypes of simian 
retroviruses (SRV-1 through SRV-8), all of which have been isolated from Asian 
macaques excepting SRV-6/Po1-Lu, which has been isolated from langurs.13,14,15 This 
group also includes a new world squirrel monkey retrovirus (SMRV).16 The prototypical 
member of the type-D retrovirus, the Mason-Pfizer monkey virus (also called SRV-3) 
was isolated from the mammary carcinoma of female rhesus macaques 17. Similar to HIV 
and SIVs, SRVs also cause immunodeficiency syndromes in macaque species.13,14  
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The well-known examples of type-B exogenous retroviruses are Mouse mammary 
tumor virus (MMTV), causing breast cancer in mice and Jaagsiekte sheep retrovirus 
(JSRV), causing lung cancer in sheep. An example of a type-B endogenous retrovirus is 
HERV-K. Both MMTV and HERV-K are exceptions to this genus as they encode 
accessory proteins. The alternative splicing of the env gene in MMTV produces two 
accessory proteins- the superantigen (Sag) protein and the Rem protein.18 The Rem 
protein helps in nuclear export of unspliced mRNA transcripts while the Sag protein 
helps in viral pathogenesis.18  The HERV-K encodes an HIV-1 Rev-like nuclear export 
protein called Rec and a tumorigenesis protein called Np9.19,20  
 
1.3.1.3 Genus: Gammaretrovirus 
The gammaretrovirus genus comprises of the largest number of simple exogenous 
and endogenous retroviruses that are found in diverse vertebrates including mammals, 
birds, reptiles and amphibians. The gammaretroviruses have a C-type morphology, and 
their genomes consist of the gag, pro, pol and env genes only.4 Presence of any accessory 
genes has not yet been reported in any members of this genus. The gammaretroviruses 
are usually associated with immunosuppression, neurological disorders and 
malignancies.4 Some of the most prominent exogenous members of this genus are the 
murine leukemia virus (MLV), feline leukemia virus (FeLV), reticuloendotheliosis virus 
(REV), and gibbon ape leukemia virus (GaLV). Examples of two extensively studied 




1.3.1.4 Genus: Deltaretrovirus 
The deltaretrovirus genus consists of only complex exogenous mammalian 
retroviruses characterized by a C-type morphology. Two notable members of this genus 
are the human T-lymphotropic virus (HTLV) and the bovine leukemia virus (BLV). 
Apart from the 4 essential retroviral genes, the deltaretroviruses also have two non-
structural accessory genes called tax and rex.10 The rex gene encodes for an analog of 
HIV-1 Rev protein called Rex.21 Rex enhances the nuclear export of unspliced or 
minimally spliced mRNA transcripts.21 The tax gene encodes for a transcriptional 
activator called Tax.22 HTLV infection in humans are associated with 
leukemia/lymphomas and neurological disorders.  
 
1.3.1.5 Genus: Epsilonretrovirus 
The epsilonretrovirus has similar morphology like the deltaretrovirus and 
comprises of only complex exogenous piscine retroviruses. The prototypical member of 
this genus is the Walleye dermal sarcoma virus (WDSV). Other examples include 
snakehead retrovirus (SnRV), perch hyperplasia retrovirus (PHV) and salmon 
swimbladder sarcoma virus (SSSV). WDSV has three accessory genes- orf a, orf b and 
orf c.23 The orf a gene encodes for a cell-cycle regulatory protein called the retroviral 
cyclin protein (rv-cyclin).10,23,24 The orf b and orf c genes encode for Orf B and Orf C 
proteins having unknown functions. 
1.3.1.6 Genus: Lentivirus 
This genus consists of complex mammalian retroviruses either having a 
characteristic conical or cylindrical core.10 Some famous examples of retroviruses of this 
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genus are the human immunodeficiency virus-1 and -2 (HIV-1 and -2), simian 
immunodeficiency viruses (SIVs), bovine immunodeficiency virus (BIV), equine 
infectious anemia virus (EIAV) and visna virus. Out of the above list, HIV-1 is well-
known for causing acquired immunodeficiency syndrome (AIDS) and resulting in very 
high death rates worldwide. The 3’ half of the HIV-1 genome contains several accessory 
genes- vif, vpr, vpu, rev, tat and nef (Figure 1.1B).10 These accessory genes encode their 
respective proteins that perform a variety of functions during the viral replication cycle. 
All primate lentiviruses do not have identical sets of accessory genes. For example, HIV-
2 and not HIV-1 has the vpx gene, and non-human primate lentiviruses like SIVs in 
rhesus macaques and sooty mangabeys lack the vpu gene. 
 
1.3.2 Subfamily: Spumaretrovirinae 
1.3.2.1 Genus: Spumavirus 
The spumaretroviruses are also called foamy viruses because of their unique 
morphology. These complex retroviruses consist of a centrally positioned uncondensed 
core with the envelope glycoproteins forming spikes on the surface giving them a foamy 
appearance.25 The virion assembly takes place within the cell cytoplasm, and the budding 
mostly occurs from the ER rather than the plasma membrane.10 The first foamy virus was 
isolated from monkey kidney cells in 1955 and thereafter, several other foamy viruses 
were isolated from diverse mammalian species. The prototypical member, the human 
foamy virus was isolated from the nasopharyngeal carcinoma of a human patient in 1971. 
However, this virus shared nearly 85-95% sequence similarity with the simian foamy 
virus isolate of chimpanzees (SFVcpz), and so it was designated as SFVcpz(hu).26 Apart 
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from the gag, pro, pol and env genes, the foamy virus genome also encodes two 
accessory genes called tas or bel-1 and bet. The Tas protein acts as a transcriptional 
transactivator and initiates transcription from the LTR.26 The exact function of bet gene is 
still unknown. However, one study suggested that the Bet protein encoded by the bet 
gene helps to counteract restriction by the host antiviral factor APOBEC3G.27 Some 
prominent examples of spumaretroviruses are the simian foamy virus (SFV), equine 






















Figure 1.3. Phylogenetic relationship among the different retroviruses belonging to 
the Orthoretrovirinae and the Spumaretrovirinae subfamilies. The Orthoretrovirinae 
subfamily consists of the alpha-, beta-, gamma-, delta-, epsilon- and lentivirus. The 
Spumaretrovirinae consists of a single genus called the spumavirus. The phylogenetic 
tree is based on the polymerase sequences of some of the representative retroviruses 










Table 1.2. Showing the different genera of the Orthoretrovirinae and the 
spumaretrovirinae subfamilies, the salient features of the genera and a few examples of 






















Subfamily Genus Morphology tRNA primer Genome-type Accessory genes Examples
Alpha C-type tRNATrp Simple none RSV
ALV
Beta B-type tRNALys-1,2 or tRNALys-3 Simple exceptions include MMTV
sag  and rem  in MMTV HERV-K
rec  in HERV-K JSRV
D-type tRNALys-1,2 or tRNALys-3 Simple none SRV-1 through SRV-8
SMRV






Delta C-type tRNAPro Complex rex and tax STLV
BLV
HTLV





Lentivirus Cylindrical or tRNALys-3 Complex vif, vpr, vpx, vpu, tat, rev HIV-1 & HIV-2











1.4 Retroviral envelope glycoprotein 
 
The retroviral envelope (Env) glycoproteins are type-I membrane proteins and are 
synthesized as single precursor proteins on the RER from a spliced viral mRNA 
transcript. The first few amino acid residues on the N-terminus of the Env precursor 
protein constitutes a hydrophobic signal peptide, which cotranslationally inserts the Env 
protein into the lumen of the RER.28 Once in the ER, the leader peptide is removed by the 
cellular protease, and the retroviral Env protein is heavily glycosylated and oligomerized 
into trimers. Glycosylation is necessary for proper protein folding and oligomerization 
ensures stable protein expression.28  The Env trimers are exported to the Golgi and a 
furin-like cellular protease recognizes a polybasic residue (such as K/R-X-K/R-R) on the 
Env precursor and cleaves it into a C-terminal surface subunit (SU) and an N-terminal 
transmembrane subunit (TM).11 Therefore, the resulting mature retroviral envelope 
glycoprotein is a heterotrimer (SU3TM3). The TM subunit consists of an ectodomain 
(protrudes outside the virion), a membrane-spanning domain (MSD) and a cytoplasmic 
tail (CT). The SU harbors the receptor binding domain and therefore determines host cell 
tropism, and the TM mediates fusion of the virion and the host cell membranes to 
facilitate viral entry.11 In the case of simple retroviruses like MMTV and MLV, the 
cleavage of the viral envelope has been shown to be essential for the envelope 
fusogenicity during viral infection.29,30 In MLV, the Env cleavage also facilitates 
anterograde trafficking and incorporation into viral particles.31 The intracellular 
trafficking mechanisms of the retroviral envelopes are still unclear. However, one study 
suggests that the AP-1 clathrin adaptor mediates HIV-1 envelope sorting from the TGN 
to the plasma membrane.32 In simple retroviruses like MLV and SRV-3, a dileucine and a 
 18 
tyrosine-based motifs in the viral envelope cytoplasmic tail have been shown to be 
critical for intracellular envelope trafficking.33 Once the envelope glycoproteins reach the 
plasma membrane, they are incorporated into the virions. The remaining Env proteins are 
endocytosed and are recycled back to the plasma membrane for virus budding and 
release. Env proteins are incorporated into the virions in three ways: i) passive 
incorporation- without involving Gag and Env interactions ii) regulated incorporation that 
involves direct interactions between the Env and Gag (usually the matrix protein in case 
of HIV-1) and iii) regulated incorporation that involves interactions between Env and 
Gag through a linker protein.28  
Apart from binding to receptors on the host cell and mediating fusion for virus 
entry, envelope glycoproteins also associate with receptor interference.34 The retroviral 
Env usually blocks the receptor-binding domain or downmodulate cell-surface expression 
of the receptor such that the viral receptor on the cell surface is not available for re-
infection by the same or other viruses. Because of this phenomenon, it is possible to 
group retroviruses into interference groups and infer the use of a common receptor, even 
when the receptors are unknown. Interference groups typically consist of closely related 
viruses, but can also comprise unrelated viruses that have converged on the same 
receptor. One such example is the RD114 and D-type interference supergroup which 
comprises of the type-D betaretroviruses and multiple exogenous and endogenous 
gammaretroviruses. All the viruses of the RDR interference supergroup use the sodium-
dependent neutral amino acid transporter, ASCT2 as the receptor.12  
The retroviral envelope glycoproteins are generally of two types- i) gamma-type 
and ii) beta-type.11 In a gamma-type retroviral envelope, the SU and TM associate 
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covalently with each other by means of an intersubunit disulfide bond and has a 
characteristic immunosuppressive domain (ISD) (Figure 1.4).11 The intersubunit disulfide 
bond formation is mediated by a CXnCC motif in the TM subunit. In contrast, the beta-
type envelope is characterized by a non-covalent association between SU and TM and the 
absence of the ISD.11 The gamma-type envelope is usually found in alpharetroviruses, 
gammaretroviruses and type-D betaretroviruses whereas the beta-type envelope is found 
in betaretroviruses and lentiviruses.11  Since the viral envelopes determine host range, the 
acquisition of a gamma-type envelope by a virus has conferred some advantages over the 
beta-type envelope. For example, the gammaretroviruses have a very diverse host range 
and infect almost all vertebrates. On the other hand, the distribution of lentivirus is 
limited to mammals. This suggests that in contrast to the beta-type envelopes, the 
gamma-type envelopes may favor cross-species transmission between the vertebrates. As 
a result of the cross-species transmission, the gammaretroviruses probably infect a wide 
range of vertebrate hosts.  
Evidence suggest that the gamma-type env gene has been swapped between 
different viral lineages by recombination on multiple occasions over a span of millions of 
years.11 Such recombination events have given rise to several recombined viruses with 
diverse host range and tissue tropism. For instance, the viral lineage that gave rise to the 
type-D retroviruses such as the SRVs, originated as a result of the recombination between 
the gag-pol sequences of a beta-like virus and the env gene of a gamma-like virus. Hence, 
the type-D retroviruses share a high degree of sequence homology in their Gag and Pol 
proteins with the betaretroviruses, but their env gene resembles that of 
gammaretroviruses.12 Some prominent examples of endogenous retroviruses with 
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gamma-type envelope include that of the Baboon endogenous retrovirus (BaEV), the 
feline RD114 and the Reticuloendotheliosis virus (REV) of chickens.11 Reports suggest 
that the gamma-type envelopes of some endogenous retroviruses have also been exapted 
for host functions. For instance, the human Syncytin-1 and the rabbit Syncytin-Ory1 are 
fusogens that have been exapted for syncytiotrophoblast layer formation during 
placentation in mammals.12,35  Thus gammaretroviral envelope glycoproteins form a 
powerful tool that helps to shed light on how the different phenomena such as host range, 
























Figure 1.4. Schematic showing a typical gammaretroviral envelope glycoprotein. A 
typical gammaretroviral envelope glycoprotein has a surface subunit (SU; orange) with a 
hydrophobic signal peptide (Sp), a transmembrane subunit (TM; red), a membrane 
spanning domain (MSD; gray), an immunosuppressive domain (ISD; blue) and a 
cytoplasmic tail (CT). The conserved CxxC and CxnCC motifs form the intersubunit 
disulphide linkage between the SU and the TM subunits. The cellular protease cleaves the 












1.5 Host restriction factors 
 
Host restriction factors (RFs) may be defined as cellular factors that block 
different stages in the viral replication cycle either by directly interfering with the viral 
proteins or indirectly by rendering the host cellular milieu non-permissive for viral 
replication.36 These RFs constitute a specialized form of innate immunity called the 
‘intrinsic immunity’. The RFs are mostly induced by interferons (IFNs), but sometimes 
they may also be constitutively expressed in certain cell types. The mechanism of 
antiviral activity of each RF is unique and is dependent on the extent of its viral targets. 
Therefore, an RF may either i) non-specifically restrict a broad range of unrelated viruses 
(e.g., tetherin), or ii) inhibit viruses in a species- or genus-specific manner (e.g., Fv4), or 
iii) inhibit viruses belonging to the same family (such as Trim-5α), or iv) inhibit unrelated 
viruses by targeting a common step in the viral replication cycle (e.g., APOBEC3G). 
Consequently, the viruses either encode dedicated antagonists or evolve their structural 
proteins to evade restriction by RFs. For example, HIV-1 counteracts Trim-5α by 
mutating its capsid protein while it encodes an accessory protein Vpu to counteract 
restriction by tetherin. The RFs have been engaged in a long-term ‘evolutionary arms 
race’ with their viral antagonists that leads to a series of adaptations and 
counteradaptations in the RFs and the viral antagonists respectively. The viral antagonists 
constantly exert a selection pressure on the RFs. As a result of the selection pressure, the 
RFs show signatures of positive selection which often form the target sites for the viral 
antagonists. Some RFs also act as pattern-recognition receptors (PRRs) and induce 
antiviral immune responses upon sensing viral infection.  
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The first RF called Fv1 was discovered in the early 1970s and was shown to 
inhibit MLV infection in mice.37 Since then, there has been a growing list of RFs; 
especially the most well-characterized ones have been identified in the primate 
lentiviruses like HIV-1 and SIVs. Some notable examples of RFs that interfere with 
primate lentiviral infection are: The Interferon-induced transmembrane proteins 
(IFITMs), Tripartite motif 5-alpha (Trim-5α), APOlipoprotein B Editing Catalytic 
subunit-like 3 (APOBEC3) G, SAMHD1 (Sterile Alpha motif and Histidine-Aspartic 
domains containing protein 1), Mx2, and tetherin (Figure 1.5). The antiviral functions and 
the viral antagonists of the above-mentioned RFs are summarized in table 1.3. 
Trim-5α recognizes and specifically binds to retroviral capsids and causes 
premature disassembly and degradation of the retroviral components to inhibit reverse 
transcription.38 The Trim-5α is composed of the RING, B-Box, coiled-coil and a SPRY 
domain. The SPRY domain is thought to be the capsid recognition domain.39 Apart from 
inhibiting primate lentiviral replication, new world monkey Trim-5α has been shown to 
inhibit SRV-3/MPMV infection.40 However, SRV-3 is resistant to restriction by old 
world monkey Trim-5α.40 As mentioned earlier in this section, the retroviruses usually 
counteract Trim-5α restriction by mutating their capsid proteins.  
APOBEC3G is a cytidine deaminase that usually gets incorporated into the 
virions in the producer cells and restricts viral replication in the target cells. It causes 
deamination of cytidines to uracil in the minus strand of the viral DNA during reverse 
transcription.38,41,42 As a result, the provirus acquires guanine to adenine mutations (often 
called hypermutations) which makes it incompetent for replication in the target cells.38,42 
There are several other members in the APOBEC3 family such as APOBEC3D, 
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APOBEC3F and APOBEC3H; all of the APOBEC3 proteins have been shown to 
suppress lentiviral replication. Consequently, the primate lentiviruses encode Vif (Viral 
infectivity factor) that prevents the incorporation of APOBEC3 proteins into the virions, 
by ubiquitination and proteosomal degradation of APOBEC3 proteins.42  
SAMHD1 is a SAM- (Sterile Alpha motif) and HD- (Histidine-Aspartic) domains 
containing protein 1 that prevents reverse transcription of primate lentiviruses in the 
myeloid cells by depleting the dNTP pools required for the viral cDNA synthesis.42,43,41 
HIV-2 and some SIVs (such as the SIVrcm, SIVsmm and SIVmac) encode the accessory 
protein called Vpx (Viral protein x) which induces ubiquitination and proteosomal 
degradation of SAMHD1.41,42 SIVagm encodes Vpr instead of Vpx that degrades 
SAMHD1.44 HIV-1 lacks Vpx and is speculated to use the host cyclin L2 for degrading 
SAMHD1.45  
RFs like Mx2, IFITM and tetherin have a broad spectrum of antiviral activity. 
IFITM proteins are entry blocks to viral replication and prevent fusion of the viral and 
host cell membranes. IFITMs are transmembrane proteins that multimerizes to form a 
network within the outer membrane leaflet and modulate the fluidity of the host cell 
membranes to prevent viral fusion. Unlike the other RFs, there are no known viral 
antagonists of IFITMs.  
Mx2 (Human Myxovirus resistance 2) is a dynamin-like GTPase that inhibits the 
nuclear import and integration of the viral PIC by a mechanism that is independent of its 
GTPase activity and instead relies on its structural dimerization.46,47 HIV-1 antagonizes 
Mx2 by introducing variations in its capsid protein.48 Tetherin is the exit block to 
retroviral replication that restricts the egress of numerous enveloped viruses. The 
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structure and the detailed antiviral mechanism of tetherin are discussed in details in the 
section 1.5.1. 
In general, restriction factor is a broad term and in addition to the well-
characterized ones, there are several other host cellular proteins that interact with viruses 
to suppress virus replication. Some of them might fulfill one or more but not all criteria 
of a well-characterized RF. Reports suggest that most RFs are inefficient against the 























Figure 1.5. Schematic showing the blocks to replication imposed by some of the 
restriction factors.  The different restriction factors are numbered and indicated by the 
red polygons. The first entry block is the membrane-spanning restriction factor called 
IFITM that prevents membrane fusion. Following entry, the uncoating of the retroviral 
capsid is inhibited by Trim-5α. APOBEC3G induces hypermutation and prevents reverse 
transcription of retroviral RNA in the target cells. SAMHD1 blocks reverse transcription 
by depleting the cellular dNTP pools. Mx2/MxB inhibits nuclear import of the pre-
integration complex. Tetherin crosslinks enveloped virions to the plasma membrane and 



















Restriction Restriction Positive Antiviral Function  Virus/es targeted Viral antagonists
Factor inducible selection
Trim-5α Yes Yes interferes with the viral Retroviruses Mutations in capsid
capsid uncoating
APOBEC3G Yes Yes induces hypermutations in the Retroviruses & Vif (lentiviruses)
provirus; inhibits reverse Hepadnaviruses GlycoGag (MLV)
transcription in the target cells Bet (Spumavirus)
SAMHD1 Yes Yes depletes dNTP pools & inhibits Lentiviruses Vpx (HIV-2 & some SIVs)
the viral cDNA synthesis Vpr (SIVagm)
IFITM Some Some prevents fusion between the viral Flaviviruses,






Mx2/MxB Yes Yes inhibits nuclear import of the  PIC primate lentiviruses Mutations in capsid
& SRV-3
Tetherin Yes Yes restricts virion release Flaviviruses, Unknown
Rhabdoviruses, Unknown
Retroviruses, Vpu, Nef & Env
Filoviruses, Env (Ebola & Marburg virus)
Paramyxovirus, F & HN (Sendai virus)
Herpesvirus, K5 (KSHV) & gM (HSV-1)




1.5.1 Tetherin- A potent block to enveloped viral release 
Tetherin (also called HM1.24) is a specific cell surface biomarker found in 
terminally differentiated B-cells that was recognized after screening of mouse 
monoclonal antibodies raised against human plasma cells.49 The tetherin gene was 
independently cloned from the synovial cells derived from human rheumatoid arthritis 
and was termed as BST2 (Bone marrow stromal cell antigen 2).50,51 The protein was 
renamed as CD317 (cluster of differentiation 317) and was seen to be constitutively 
expressed at low levels in monocytes, macrophages, plasmacytoid dendritic cells and 
CD34+ T-cells.52 Tetherin is also widely expressed in salivary glands, gastrointestinal 
tract, pancreas, spleen, gall bladder and kidney tissues.25  
In humans, the chromosome 19 contains a single tetherin gene.50  However, 
ruminants like cows, sheep and goats have two copies of this gene due to gene 
duplication.53,54 The tetherin promoter contains a single interferon regulatory factor (IRF) 
binding site and is strongly induced by IFN-α.55 In some species and certain cell types, 
tetherin expression is also induced by IFN- b, -g, -l3, -t and -w.56,53,57,58,59,60 Evidence 
suggest that in absence of IFNs,  TLR 3, TLR 8 and IL-27 stimulate tetherin expression 
in the PBMCs.55,61  
Tetherin has implications in the structural organization of cells. Tetherin aids in 
anchoring the apical actin network and in the stabilization and maintenance of Golgi 
network and membrane microdomain structures.62,63,64,65 Tetherin also acts as a PRR and 
upon sensing viral infection induces antiviral response by triggering NF-κB 
activation.66,67,68 Since both mouse and human-derived tetherin-specific monoclonal 
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antibodies had anti-tumor activity, several research groups proposed that tetherin can also 
be used as an immunotherapeutic agent against cancer.69,70  
 
1.5.2 Discovery of tetherin as a host restriction factor 
In certain cell lines like HELA, Jurkat T and Hep 2, HIV-1 accessory protein, 
Vpu was indispensable for HIV-1 viral release.71,72,73 Hence, these cells were referred to 
as non-permissive cells. Contrary to these, HOS, COS, HEK-293T, HT-1080 and CV-1 
cells were known as permissive cells as these cells permitted efficient HIV-1 particle 
release even in the absence of Vpu.73,74,75 These observations suggested an absence of a 
host co-factor or the presence of a host restriction factor in the non-permissive cell lines. 
Further studies involving heterokaryons formed by permissive and non-permissive cells 
indicated that the non-permissive cells endogenously expressed a restriction factor which 
was counteracted by Vpu.76,77 Thereafter several cellular factors like TASK-1 and CAML 
were thought to be the targets of Vpu.78,79  
In 2008, the Bieniasz laboratory identified ‘tetherin’ as a host restriction factor.80 
They pointed out that Vpu expression in trans was necessary for the efficient release of 
HIV-1 virions in the non-permissive HeLa cells but not in HT1080, HEK-293T, Cos-7 
and HOS cells. However, when HT1080, HEK-293T cells and HOS cells were induced 
by IFN-α, HIV-1∆Vpu virion release was inhibited. In contrast, when these IFN-α 
stimulated cells were treated with subtilisin protease, the trapped virions were released. 
Such an observation suggested the presence of a membrane-associated interferon-
inducible antiviral protein in the non-permissive cell lines and the absence of the same in 
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the permissive cells.75,80 This membrane-bound antiviral factor was termed as ‘tetherin’ 
and was recognized as a potent inhibitor of viral release.80  
The Guatelli laboratory also made similar observations almost at the same time.81 
Using immunofluorescence microscopy, this group was able to visualize the co-
localization of Vpu and tetherin within the endosomal compartments. The Gag proteins 
of both wild-type HIV-1 and HIV-1∆Vpu virus were also shown to co-localize with 
tetherin within the endosomes and at the plasma membrane.81 Additionally, their research 
showed that Vpu downregulated tetherin from the cell surface.81 
Interestingly, the antiviral function of tetherin was not only restricted to HIV-1 
(retrovirus) but was also observed in case of Ebola virus (filovirus) release, suggesting 
that the restriction factor worked in a non-specific manner.75  
 
1.5.3 Structure of tetherin 
Tetherin is 181 amino acids long type II integral membrane protein that has a 
molecular mass ranging between 30 kDa to 38 kDa.50 It is characterized by a small 
amino-terminal cytoplasmic tail (CT), an α-helical single-pass transmembrane domain 
(TM), an coiled-coil extracellular domain (EC) and a carboxy-terminal glycosyl-
phosphatidylinositol (GPI) anchor (Figure 1.6A).63  The C-terminus end of tetherin is 
cleaved off and replaced by the GPI anchor within the ER.65 Tetherin localizes in the 
cholesterol-rich membrane microdomains through its GPI anchor. It should be noted that 
these lipid rafts also serve as preferable virus budding sites. Both CT and GPI anchors 
play a very important role in physically crosslinking the virions to the host cell 
membrane. Deletion of either of the membrane anchors inhibit the ability of tetherin to 
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block viral release.82 Apart from localizing at the plasma membrane, tetherin is also 
found within TGN, early and recycling endosomes.  
The tetherin CT contains a highly conserved non-canonical tyrosine motif (YxY) 
which favors recycling of tetherin between the cell membranes and the endosomal 
compartments. The YxY motif mediates endocytosis by binding to AP-1 and AP-2 
clathrin adaptors.57,62 There are two N-linked glycosylation sites on tetherin ectodomain 
(N65 and N92), that are thought to have implications in the proper folding of tetherin and 
its anterograde transport.82 Tetherin dimerizes by three cysteine residues (C53, C63, C91) in 
its EC domain. This homodimerized extracellular domain confers conformational 
flexibility necessary for virion tethering.82,83 Mutations in all three cysteine residues in 
the ectodomain inhibited tetherin dimerization and significantly reduced tetherin’s ability 
to inhibit HIV-1∆Vpu viral release. However, mutations in the N-linked glycosylation 
sites had no such effects.82,84,85 Reports suggest that tetherin ectodomains tetramerize 
through a 4-helix bundle interaction and this association seemed dispensable for 
tetherin’s antiviral function.82,83 Therefore, the significance of such a configuration 
remains obscure. However, one study speculated that the tetherin tetramers might be 
essential for proper trafficking of tetherin.86 
In 2010, an X-ray crystallography study was conducted to solve the partial 
structure of tetherin ectodomain.84 The authors revealed that the ectodomain of tetherin 
forms a 90 Å long rod-like, parallel, α-helical coiled-coil. Small angle X-ray scattering 
indicated that the N-terminal portion of this coiled-coil extending all the way up to the 
lumenal end of the TM domain is inclined at a slight angle.84 There are structural 
irregularities within the coiled-coil, caused by the presence of some destabilizing residues 
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at the core of the α-helix. The formation of coiled-coil dimer restores this structural 
instability. The structural irregulaties maintain the flexibility of the ectodomain during 
tethering of the budding virions. The entire ectodomain is nearly 170 Å and loses its 
structural stability in the absence of the disulfide bonds.84  
In the human tetherin, a leaky Kozak sequence is present before the methionine at 
position 13.87 Therefore, this methionine also serves as an alternate start codon leading to 
the formation of a shorter tetherin isoform that lacks the YxY endocytosis motif and 
mostly localizes at the cell surface.87 Shorter tetherin isoforms are also present in cats, 
elephants, horses and guinea pigs.65,88  
The human tetherin orthologue lacks the five amino acids (14GDIWK18) in its 
cytoplasmic tail that are present in the other non-human primate tetherins. These five 
residues are also absent in Denisova and Neanderthal (the archaic humans), suggesting 
that the protective deletion arose roughly 800,000 years ago.89  
 
1.5.4 Antiviral activity of tetherin 
Tetherin dimer physically crosslinks budding enveloped virions to the host cell 
membrane and prevents their spread from one infected cell to another (Figure 1.6B). The 
tethered virions are internalized into the infected cells by endocytosis. A RING-type E3 
ubiquitin ligase called Rabring7/BCA2 (Breast cancer-associated gene 2) interacts with 
tetherin and directs the trapped virions to the CD63-positive endosomes.90 The tethered 
virions accumulate within the late endosomes and are finally degraded by lysosomal 
enzymes (Figure 1.6B).90 The most unusual facet of tetherin is its non-specific mode of 
action. Virion tethering does not require recognition of any virus-specific molecular motif 
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but instead results from the anchoring of the N-and C- termini between the virion and 
cellular membranes. Therefore, in theory, tetherin can restrict the release of any entity 
that buds out of the cell; be it an enveloped virus or a membrane-bound vesicle.  
A study conducted by Perez et al., have shown that an artificial tetherin (ART-
tetherin) protein having identical structural domains (CT/TM, EC and GPI anchor) 
formed from three heterologous proteins exhibited a similar degree of restriction in the 
release of HIV-1∆Vpu and Ebola virus.82 This finding indicates that the putative 
membrane topology and not the primary sequence homology to tetherin is necessary for 
tetherin’s antiviral function.82 The artificially engineered tetherin consisted of the 
transferrin receptor (TfR) TM domain, the coiled-coil domain of dystrophia myotonica 
protein kinase (DMPK) and the C-terminus GPI anchor of the urokinase plasminogen 
activator receptor (uPAR).82 Similar to native tetherin, the deletion of either of the 
membrane anchors of ART-tetherin disrupted its antiviral function. However, HIV-1 Vpu 
was unable to counteract ART-tetherin and promote viral release.82 This observation 
suggested that Vpu requires the recognition of specific residues within the native tetherin 
for its anti-tetherin activity. 
Recently, Venkatesh and Bieniasz proposed that tetherin dimer acquires an ‘axial 
configuration’ and inserts either its N-termini pairs or C-termini pairs into the viral 
membranes during virion restriction.91 Additionally, they noticed that there was a three- 
to a five-fold preference for the insertion of the GPI anchor into the viral membrane than 
into the host cellular membranes.91  Inserting the N-termini in the host plasma membrane 
probably favors interaction with its cellular endocytosis machinery, and this could 
possibly explain the above preference.91 A quantitative western blot analysis indicated 
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that a minimum of 12 tetherin dimers are required to cross-link a single virion to the 
cellular membrane.91 
Tetherin has a broad spectrum of antiviral function against several families of 
enveloped viruses that includes retroviruses (e.g., alpha-, beta-, gamma-, delta-, lentivirus 
and spumaviruses),92,93,94 paramyxovirus (Nipah virus),95 rhabdovirus (VSV),96 
arenaviruses (Machupo virus and Lassa virus),97,95 gamma-herpes virus (Kaposi’s 
sarcoma-associated herpes virus; KSHV),98 togavirus (Chikungunya virus), flavivirus 
(Dengue and Hepatitis C viruses)99 and filoviruses like Ebola virus and Marburg 
virus.100,92 Viruses like HSV-1 and HCoV-229E that bud from intracytoplasmic vesicular 
membranes are also restricted by tetherin.101,102 The tetherin orthologue from the Gray-
handed night monkey has a S164T mutation in its ectodomain and is the only tetherin 




















Figure 1.6. Tetherin and its antiviral activity. (A) Structure of a tetherin dimer. The 
different domains of tetherin are represented in this figure namely: CT= Cytoplasmic tail, 
TM= Transmembrane domain, EC= Ectodomain and GPI= glycophosphatidylinositol 
anchor. Cysteine residues on the EC forms disulfide bridges and help in the dimerization 
of tetherin molecules. Dimerization is imperative for its antiviral function. (B) Antiviral 
action of tetherin. Tetherin dimers tether virions to the host cell membrane and restrict 
their egress. Tetherin traps viral particles by targeting their host cell-derive lipid 
envelope. The tethered virions accumulate within the early and late endosomes and are 




1.5.5 Role of tetherin in promoting viral pathogenesis 
Retroviruses mostly disseminate within the host by cell-free transmission in 
which the viruses are released into the extracellular milieu.104,105 However, sometimes the 
cell-free virus transmission may become unfeasible. Under such circumstances, the 
viruses prefer to disseminate via direct cell-cell contacts, and this is facilitated by the 
formation of virological synapses.104,105,106 The formation of virological synapse involves 
rearrangement of the cytoskeleton, and interactions between the viral envelope 
glycoprotein on the donor cell and the receptor on the target cell. Although tetherin is 
well-known for inhibiting cell-free virus transmission, some researchers believe that 
tetherin allows cell-cell virus transmission.107,108,109 To investigate the role of tetherin in 
the cell-cell transmission of HIV-1, Jolly et al., performed a flow-cytometry based 
quantitative cell-cell transmission assay. They noticed that tetherin accumulated at the 
virological synapse (VS) and increased VS formation in HIV-1∆Vpu infected CD4+ T-
cells compared to the wild-type HIV-1 infected CD4+ T-cells.108 In contrast, siRNA-
mediated knockdown of endogenous tetherin expression reduced VS formation and cell-
cell dissemination of both wild-type and mutant HIV-1 indicating that tetherin may be 
critical for cell-cell viral spread.108 However, this functional attribute of tetherin is still 







1.6 Viral antagonists of tetherin 
As mentioned earlier, tetherin has a non-specific mode of action and does not 
require the recognition of any viral proteins for restriction. Therefore, the viruses cannot 
counteract tetherin by acquiring escape mutations in their structural proteins. Different 
enveloped viruses have evolved various tetherin-evasion mechanisms. Some viruses 
actively evade tetherin-mediated restriction by encoding dedicated tetherin antagonists, 
while others (like HIV-2 and Ebola) use their envelope glycoproteins as tetherin 
antagonists (Figure 1.7). In both the cases, the tetherin antagonists either sequester 
tetherin within the endosomal compartments or prevent anterograde transport or recycling 
of tetherin. Some other viruses exclude tetherin and bud from membrane domains lacking 
tetherin, or spread by direct cell-cell contact. Lastly, certain viruses inhibit the interferon 
pathway such that the sensors of viral infections do not trigger tetherin expression.110,111 
The different viral strategies for tetherin-antagonism are discussed in the following 
sections. 
 
1.6.1 Viral accessory proteins as tetherin antagonists 
Among the primate lentiviruses, SIVs of Old world monkeys lack a functional 
Vpu gene and encode an accessory protein called Nef (negative regulatory factor) to 
overcome restriction by their respective simian host tetherins.112,113,114,115 These include 
the Nef proteins of SIVs from rhesus macaques, sooty mangabey, pig-tailed macaques, 
blue monkey, African-green monkey and chimpanzees. Nef is a 27-35kDa myristoylated 
cytosolic protein and is well-known for modulating the expression of numerous 
membrane proteins.116,117 The Nef protein is characterized by a globular core domain, an 
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N-terminus region and a C-terminus flexible loop.118 The di-acidic residues (155EE156) and 
an acidic patch (62EEEE65) in the globular domain interacts with COP proteins (β-COP) 
and PACS1 and -2 proteins (phosphofurin acid cluster sorting proteins) 
respectively.119,120,121 The C-terminus loop of Nef contains a 160D/ExxxLL165 motif that 
recruits the clathrin adaptors. Thus, although the general function of Nef is to link the 
vesicular machinery with its protein targets for endocytosis, this general function also 
forms the basis of tetherin-antagonism in Nef. SIV Nef protein not only downregulates 
the surface expression of CD4, CD28, MHC class I and class II, it is also reputed for 
antagonizing tetherin by downmodulating non-human primate tetherin levels from the 
cell surface.112,114,116 The specificity of the Nef protein of SIVmac (SIV of rhesus 
macaque) for rhesus tetherin mapped to a five amino acid motif (14G/DDIWK18) in the 
rhesus tetherin cytoplasmic tail that are absent from the human tetherin orthologue.112 
Thus, SIVmac Nef is non-functional against human tetherin and fails to downregulate 
cell surface expression of human tetherin. The anti-tetherin activity of SIV Nef is usually 
species-specific and no studies have been conducted till date to determine if it can 
counteract other mammalian tetherin orthologues. 
The detailed mechanism of SIVmac Nef’s anti-tetherin function was elucidated by 
the Evans laboratory in 2013.122 They pointed out that the mechanism of tetherin evasion 
in Nef was dependent on clathrin-mediated endocytosis. The researchers reported that 
highly conserved 160D/ExxxLL165 motif in the C-terminus loop of Nef protein is 
necessary for Nef’s anti-tetherin activity.123,122,124 Mutations within this motif impaired 
Nef’s ability to downregulate cell surface tetherin expression.122,124 Using alanine 
scanning mutagenesis, Serra-Moreno et al., identified a number of residues within the 
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globular core (27 residues), N-terminus (9 residues) and C-terminus (7 residues) of Nef 
that were imperative for Nef-mediated tetherin-antagonism.122 This suggests that the anti-
tetherin function of Nef is not dependent on a single structural domain but results from 
the interactions among all the Nef domains. Nef was also shown to directly associate with 
the rhesus tetherin cytoplasmic tail and remove rhesus tetherin from viral budding 
sites.122  
Kluge et al., revealed that the Nef protein of HIV-1 O group have also evolved to 
antagonize human tetherin.125 The domain of interaction between HIV-1 O Nef and 
human tetherin mapped to the residues 5SYDY8, which lie in close proximity to 
14G/DIWK18 motif.125 Mutations in 5SYDY8 residues disrupted Nef’s ability to reduce 
cell surface human tetherin levels. HIV-1 O Nef also sequestered newly formed human 
tetherin within the TGN and prevented their anterograde transport to the plasma 
membrane.125  Recently, it has been reported that the HIV-1 group O strain RBF206 Vpu 
counteracts both long and short isoforms of human tetherin in a non-specific manner.126  
Unlike most SIVs, HIV-1 groups M and N antagonize the antiviral effect of 
human tetherin by encoding another accessory protein called Vpu (Viral protein 
U).80,112,93,127,113 The Vpu proteins of the immediate predecessors of HIV-1, SIVcpz and 
SIVgor lost their ability to antagonize tetherin.113,128 Hence, both SIVcpz and SIVgor 
encode Nef to evade restriction by tetherin.113,128 In contrast, the Vpu proteins of SIVs 
from greater spot-nose monkey, mustached monkey, Dent’s mona monkey and Mona 
monkey are able to antagonize their respective host tetherins.113,128 The HIV-1 group M 
Vpu specifically antagonizes human tetherin but is sensitive to non-human primate 
tetherins.129,130 Vpu is a small transmembrane protein that has a very short luminal 
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region, a 23 amino acids long α-helical transmembrane domain and a cytoplasmic tail 
consisting of two α-helices and a flexible hinge. Vpu interacts with the TM domain of 
human tetherin to evade restriction by human tetherin.131,132 The residues A14, A18 and 
W22 in the transmembrane domain of Vpu are critical for tetherin-antagonism.133 
Although the exact role of these residues in tetherin-antagonism is still dubious. The 
specificity of Vpu for human tetherin maps to the residues I34, L37, L41 and T45 in the 
transmembrane domain of human tetherin.134 
The mechanism of tetherin-antagonism by HIV-1 group M Vpu protein involves 
ubiquitination and proteosomal degradation of human tetherin.135 Vpu has a highly 
conserved 51DSGxxS56 motif present in between the two α-helices and undergoes 
phosphorylation by casein kinase-II enzyme. This phosphorylation event favors the 
recruitment of the β-transducing repeat-containing protein (βTrCP) subunits of Skp1-
Cullin1-F-box ubiquitin ligase, which results in ubiquination followed by proteosomal 
degradation.136 However, the exact cytoplasmic tail residues of human tetherin that are 
targeted for ubiquitination have not yet been identified.135 It should be mentioned in this 
regard that the shorter isoform of human tetherin is relatively resistant to Vpu suggesting 
that some or all of the first twelve residues in the human tetherin CT might be crucial for 
ubiquitination.87 The loss of interaction between βTrCP and the Vpu cytoplasmic domain 
renders Vpu sensitive to human tetherin.137,138,139  
Two independent studies have proposed that Vpu prevents the anterograde 
transport of newly synthesized tetherins and inhibits recycling of tetherin between the 
TGN and the cell surface.140,141 The 59ExxxLV64 motif in the second α-helix of the Vpu 
CT impairs tetherin trafficking, and removes human tetherin from viral assembly 
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sites.132,142 The 59ExxxLV64 motif of Vpu also interacts with AP-1 clathrin adaptor and 
causes internalization of Vpu-tetherin complex within the endosomal compartments.143,144 
Thereafter, the Vpu-tetherin complex undergoes ubiquitination and lysosomal 
degradation. The phosphorylation of S52 and S56  residues has also been shown to be 
critical for the recruitment of AP-1 and AP-2 clathrin adaptor proteins suggesting that the 
phosphorylation step leads to two independent events: i) βTrCP-dependent ubiquitination 
and ii) clathrin-mediated endocytosis.145 The cytoplasmic tail of HIV-1 group N Vpu 
protein also contains a similar 59DxxxLV64 motif and potently antagonizes human 
tetherin.146 Interestingly, a recent report suggested that some alleles of HIV-1 group M 
Nef proteins are also able to evade tetherin-mediated restriction by downregulating 
human tetherin from the cell surface.147 Arias et al., showed that the longer tetherin 
isoform and not the shorter isoform was sensitive to group M Nef. HIV-1 M Nef was 
shown to physically interact with human tetherin by targeting the first 12 residues in the 
human tetherin CT that are absent in the shorter isoform.147 This research elucidates that 
in absence of a functional Vpu protein, HIV-1 group M Nef proteins may adapt to evade 
tetherin-mediated restriction.147 
The Kaposi’s sarcoma herpes virus (KSHV) encodes a RING-CH E3 ubiquitin 
ligase protein called K5 that antagonizes human tetherin.98,148,149 K5 targets the lysine 
residues at position 18 and 21 in the cytoplasmic tail of human tetherin for ubiquitination 
of tetherin.98 Glycosylation of tetherin is necessary for the anti-tetherin activity of K5 
suggesting that the interaction between tetherin and K5 takes place within vesicular 
compartments outside the ER.149  
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Studies have shown that the non-structural proteins of Chikungunya virus (Nsp1) 
and Influenza virus (NS1) promote virion release in the presence of tetherin.137,150,151 
Additionally, the Influenza A virus neuraminidase proteins are also known to counteract 
tetherin by an undefined mechanism.152 
1.6.2 Viral envelope glycoproteins as tetherin antagonists 
HIV-2 arose as a result of independent cross-species transmission of SIV from 
sooty mangabey (SIVsmm) into humans, and unlike HIV-1, HIV-2 lacks a Vpu gene. 
Previous studies indicated that the envelope (Env) glycoprotein of HIV-2 had Vpu-like 
activity, and enhanced HIV-1∆Vpu particle release in the non-permissive cell lines.153 In 
2009, Tortorec et al., demonstrated that HIV-2 group A envelope potently antagonized 
human tetherin, and this Env-mediated tetherin-antagonism was dependent on the 
proteolytic cleavage of the envelope into its respective glycoprotein subunits (gp120 and 
gp41).93 HIV-2 Env reduced cell surface human tetherin levels without affecting the total 
cellular tetherin levels.93,154 A conserved tyrosine-based endocytosis motif (GYXXφ) in 
the gp41 subunit of the HIV-2 Env was shown to be critical for this function.93 The 
interaction between HIV-2 Env and human tetherin mapped to the ectodomain of both the 
proteins, and this interaction was necessary but not sufficient for tetherin-antagonism by 
HIV-2 Env.93,155 Additionally, the alanine residues at position 97, 100, 104 and 107 in the 
human tetherin ectodomain rendered human tetherin sensitive to HIV-2 Env.155 A more 
recent study indicated that the asparagine residue at position 659 (N659) in the HIV-2 Env 
TM subunit is indispensable for its tetherin-antagonism.156 Mutation of this  residue to an 
aspartate impaired the ability of HIV-2 Env to counteract human tetherin.156 HIV-2 Env 
also sequestered tetherin within the TGN without causing its degradation.93,154  
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The discovery of the tetherin-antagonism in HIV-2 Env was indeed very 
significant as it was the first evidence of tetherin-antagonism in a retroviral envelope 
glycoprotein. Thereafter, several independent research groups started hunting for 
tetherin-antagonism in other retroviral envelope. Recently, Heusinger et al., proposed that 
the envelope glycoproteins of some isolates of SIV from sooty mangabey (SIVsmm) 
exhibit anti-tetherin activity.157 They proposed that since SIVsmm has adapted both the 
Nef and the envelope glycoprotein to counteract tetherin; and this possibly accounts for 
the successful cross-species transmission of SIVsmm into humans on nine different 
occasions.157  
The presence of tetherin-antagonism in a simian retroviral envelope was first 
demonstrated by the Towers laboratory in 2009.158 They found out that in the absence of 
a functional Nef protein, the Env of SIV from tantalus monkey (SIVtan; a distant relative 
of HIV-1) was able to counteract human as well as some non-human primate tetherin 
orthologues.158  Like HIV-2 Env, the SIVtan Env also downregulated cell surface human 
tetherin levels and the specificity of the Env for tetherin mapped to the alanine residue at 
position 100 in the ectodomain of human tetherin.158  
In 2011 the Evans laboratory demonstrated that the envelope glycoprotein of a 
pathogenic nef-deleted SIV of rhesus macaques (SIVmac∆nefP) acquired the ability to 
antagonize macaque tetherin after serial passage in the host.159 This tetherin-adaptive 
viral envelope was referred to as EnvITM, where ITM stands for improved 
transmembrane. The ITM was previously shown to restore pathogenicity of 
SIVmac∆nefP in rhesus macaques.160 Serra-Moreno et al., showed that the EnvITM 
physically associates with rhesus tetherin and downmodulates rhesus tetherin from the 
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cell surface.159 Grafting of the EnvITM cytoplasmic tail onto a heterologous protein 
restored resistance to tetherin suggesting that the EnvITM CT was sufficient for 
counteracting tetherin. The tyrosine residue at position 721 in the EnvITM was identified 
as the viral determinant of tetherin-antagonism. Unlike SIVmac Nef, the target of 
EnvITM overlapped a stretch of ten amino acids in the rhesus tetherin CT.159  
This research raises the possibility that several such naturally occurring SIVs 
might also be able to adapt their envelope glycoproteins to antagonize their respective 
host tetherins in the absence of a dedicated tetherin antagonist (such as SIV Nef or HIV-1 
Vpu). However, in reality adapting a viral envelope glycoprotein for tetherin-antagonism 
might have its consequences on viral fitness. For instance, since both HIV-2 Env and 
EnvITM sequester tetherin within the endosomal compartments, this might lead to a 
reduction in the anterograde trafficking of the Env proteins and a consequent decrease in 
the infectious viral titer. In order words, this might lead to a reduction in viral 
pathogenicity. 
The envelope glycoprotein of feline immunodeficiency virus (FIV) has also been 
shown to antagonize carnivore tetherins by an unknown mechanism that does not require 
the downregulation or degradation of tetherin but instead results from the efficient 
incorporation of the envelope glycoprotein into the FIV particles.88,161 FIV Env 
expression in trans rescues env-defective FIV particles but not Vpu-deleted HIV-1 from 
tetherin suggesting that the anti-tetherin function of FIV Env is specific to FIV.161 
Western blot analysis revealed that there was an enhancement in the wild-type FIV 
particle production compared to the env-defective mutant FIV particles in the presence of 
tetherin.161 This observation led the investigators to hypothesize that tetherin might be 
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functioning as a co-factor rather than a restriction factor during FIV budding and 
release.161  
Yin et al., reported that envelope glycoprotein of the equine infectious anemia 
virus (EIAV) antagonized tetherin in a species-specific manner.162 They observed that the 
transient expression of EIAV Env was sufficient to rescue env-deleted EIAV from equine 
tetherin but not from human tetherin.162 Additionally, data from the co-
immunoprecipitation assay indicated that EIAV Env physically interacts with equine 
tetherin but not with human tetherin.162 Interestingly, the EIAV Env expression did affect 
the cellular distribution of equine tetherin but it did not degrade equine tetherin.162 It 
might be possible that the EIAV Env sequesters tetherin within the intracellular 
compartments thereby prevents the recycling of tetherin as well as anterograde transport 
of de novo synthesized tetherins. However, this research needs further experimental 
validation because it is possible that the transient expressions of tetherin and the viral 
envelope constructs may have impacted the experimental results. 
By far, most of the exogenous retroviral envelope glycoproteins have been 
characterized as tetherin antagonists. To date, there has been single evidence that 
suggests that an endogenous retroviral envelope glycoprotein might also function as a 
tetherin antagonist. A study conducted by the Dewannieux laboratory showed that the 
HERV-K Env protein has anti-tetherin function against human and OWM tetherins.163 
Co-immunoprecipitation experiments indicated a possible physical interaction between 
the SU subunit of the HERV-K Env and human tetherin. However, this interaction alone 
was not sufficient for  efficient tetherin-antagonism.163 Similar to EIAV and FIV Envs, 
the HERV-K Env does not downmodulate or degrade tetherin.163 Therefore, unlike the 
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primate lentiviral tetherin antagonists, HERV-K Env lacks a distinct tetherin-evasion 
mechanism and requires further investigations. 
The first evidence for Env-mediated tetherin-antagonism in a filovirus envelope 
glycoprotein was reported by the Bates laboratory in 2009.100 The investigators reported 
that the Ebola virus glycoprotein (GP) exhibited tetherin-antagonism against human, 
murine and short isoform of feline tetherin.100,161 Ebola GP also antagonized artificially 
engineered tetherin (ART-tetherin) and promoted virion release.100,164 This suggest that 
the anti-tetherin activity of Ebola GP does not require the recognition of any specific 
sequence/s in tetherin. The transient expression of Ebola GP also rescued a heterologous 
virus from tetherin.100 A recent study proposed that the membrane spanning domain 
(MSD) of the GP2 subunit and the glycan cap of the GP1 subunit of Ebola glycoprotein 
are critical for tetherin-antagonism.165 However, the Ebola GP neither downmodulates 
cell surface expression of tetherin nor degrades it.164 Unlike HIV-2 Env, tetherin-
antagonism is also not dependent on the proteolytic cleavage of the viral glycoprotein.100 
Therefore, additional studies are required to- decipher the tetherin-evasion mechanism in 
Ebola GP and identify the tetherin domains targeted by the Ebola GP for tetherin-
antagonism.  
Unlike KSHV, the herpes simplex virus-1 and -2 (HSV-1 and HSV-2) do not 
encode any accessory protein for tetherin-antagonism. Reports suggest that these viruses 
use their envelope glycoprotein to evade restriction by human tetherin.101,166 The 
envelope glycoprotein gM of HSV-1 exhibits moderate levels of anti-tetherin against 
human tetherin.101 Another study pointed out that HSV-1 may also promote viral release 
by encoding the virion host shut-off protein (Vhs) which depletes the tetherin mRNA 
 47 
transcripts.167 In contrast, multiple envelope glycoproteins of HSV-2 (such as gB, gD, gH 
and gL) actively antagonized human tetherin by downregulating cell surface human 
tetherin levels.166 The envelope glycoproteins of Sendai virus (paramyxovirus): the fusion 
protein (F) and the haemagglutinin-neuraminidase protein (HN) have been reported to 
degrade tetherin to evade tetherin-mediated restriction.168 
The different viral antagonists of tetherin and their tetherin-evasion mechanisms are 





























Virus Family Antagonist Species- Tetherin domain Mechanism of tetherin-
specificity targeted antagonism
HIV-1 Group M & N Retroviridae Vpu Human, gorilla & TM Downregulation
Chimpanzee
HIV-1 Group O Retroviridae Nef Human CT Downregulation
HIV-2 Retroviridae Envelope Human EC Downregulation
SIVgsn, SIVmus, SIVmon Retroviridae Vpu Simian TM Downregulation
& SIVden
SIVcpz, SIVgor, SIVmac, SIVsyk, Retroviridae Nef Simian CT Downregulation
SIVrcm, SIVsmm, SIVagm
SIVmac∆nefP Retroviridae EnvITM Rhesus Maaque CT Downregulation
SIVtan Retroviridae Envelope Human & OWMs EC Downregulation
FIV Retroviridae Envelope Canine & Feline Unknown Unknown; requires Env 
incorporation into virions
EIAV Retroviridae Envelope Equine Unknown Unknown
HERV-K Retroviridae Envelope Human & OWMs Undetermined Unknown
Ebola Filoviridae Ebola GP Human, mouse Unknown Unknown
& ART-tetherin
KSHV Herpesviridae K5 Human CT Downregulation
HSV-1 Herpesviridae gM Human Unknown Unknown
HSV-2 Herpesviridae gB, gD, gH & gL Human Unknown Downregulation
Chikungunya virus Togaviridae Nsp1 Human Unknown Downregulation
Influenza virus Orthomyxoviridae NS1 & NA Human Unknown Unknown; impedes tetherin
induction












Figure 1.7. Viral antagonists of tetherin and their domains of interaction. HIV-1 
encodes an accessory protein Vpu (blue) that antagonizes human tetherin by targeting the 
transmembrane domain of human tetherin. SIVs encode another accessory protein called 
the Nef (brown) that antagonizes their respective simian host tetherin by targeting the 
tetherin cytosolic domain. Kaposi’s sarcoma herpes virus (KSHV) encodes K5 (pink) 
protein that ubiquitinates human tetherin by targeting the lysine residue at position 18 in 
the cytoplasmic tail of human tetherin. Viruses like Ebola and HIV-2 use their envelope 
glycoproteins (the SU subunit shown in orange and the TM subunit shown in red) as 

















1.7 Concluding remarks 
 
To date tetherin-evasion mechanisms have been extensively studied in complex 
retroviruses like HIV-1 and SIV that encode Vpu and Nef respectively to counteract 
restriction by their respective host tetherins.80,112 The envelope glycoproteins of Ebola 
virus, HSV-1 and HERV-K have been shown to function as tetherin antagonists but their 
mechanism of tetherin-antagonism is not well-defined. The mechanism by which 
numerous simple retroviruses (such as the alpharetroviruses, betaretroviruses and 
gammaretroviruses) evade restriction by tetherin is still unknown. Therefore, my research 
focused on determining whether simple retroviruses evade restriction by their host 
tetherins, and if so, on delineating the mechanism of evasion. This research stemmed 
from the observation that SRV-3, a simple type-D retrovirus was sensitive to restriction 
by human tetherin 92. However, given that the natural host of SRV-3 is the rhesus 
macaque and together with the published reports that rhesus macaque tetherin is 
functional against other retroviruses both in vitro and in vivo,112 I hypothesized that SRV-
3 must be resistant to restriction by rhesus macaque tetherin. I have identified the SRV-3 
envelope glycoprotein as a potent tetherin antagonist and have also expanded the research 
to simple retroviruses outside the betaretrovirus genus. This research has finally opened 
the door to the discovery that tetherin-antagonism may be a novel and conserved function 





































2.1.1   Proviral plasmids 
The full-length SRV-3 proviral plasmid (pSARM4) was a gift from Dr. Eric Hunter, 
Emory Centre for AIDS Research at the Emory University, Atlanta, GA. Song et al., has 
previously described the construction of these plasmids.169 In the pSARM-eGFP proviral 
plasmid, the functional env gene was replaced with an EGFP.170 This plasmid was used in 
the single-cycle virus release assays to produce the SRV-3∆env. The SIVmac239-
VIEGFP plasmid (obtained initially from the Hung Fan laboratory at the University of 
California, Irvine, CA) was modified to express the Gag and Pol proteins.171 The 
SIVmac239-VIEGFP plasmid was used for transfections in the single-cycle VLP release 
assay to produce SIV particles, which lack both functional nef and env genes; these viral 
particles are referred to as SIVmac239∆nef∆env virus in this dissertation.  
2.1.2   Tetherin plasmids 
The pCDNA3.1-based tetherin orthologues from human, rhesus macaque, sooty 
mangabey and pig-tailed macaque as well as human-rhesus tetherin reciprocal chimeras 
and cytoplasmic tail mutants were kindly provided by Dr. Ruth Serra-Moreno, Texas 
Tech University, Lubbock, TX. The detailed strategies of cloning these tetherin 
expression constructs have been previously described by the Evans laboratory.112  Using 
the appropriate species-specific tetherin-HA forward and tetherin-HA reverse primers, an 
ectodomain-HA epitope was added to the ectodomain of all the tetherin expression 
constructs by site-directed mutagenesis. The HA-epitope was inserted after residue 131 in 
human tetherin and after residue 134 in case of all the OWM tetherins. All of these HA-
tagged tetherin orthologues were amplified by PCR using their respective species-specific 
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tetherin-AgeI forward and tetherin-BamHI reverse primers. The newly amplified HA-
tetherin orthologues were subcloned into a retroviral packaging vector, pQCXIP (having 
the puromycin-resistance marker) using AgeI and BamHI as restriction sites. HA-tagged 
tetherin orthologues from baboon (Accession XP_003915187), squirrel monkey 
(Accession XP_003942316), cat (Accession NP_001230014) and dog (Accession 
XP_865603) were synthesized by ThermoFisher Scientific GeneArt Gene Synthesis and 
Services. These constructs were also amplified by PCR using their respective species-
specific tetherin-AgeI forward and tetherin-BamHI reverse primers and then subcloned 
into pQCXIP. In order to clone the African-green monkey (AGM) tetherin orthologue, 
RNA was isolated from Vero cells using Trizol reagent (Ambion/Life Technologies). 
Two-step RT-PCR was done to procure the AGM-tetherin cDNA by using Transcriptor 
First Strand cDNA Kit (Roche) and anchored-oligo(dT)18 primer. The AGM-tetherin 
cDNA was amplified using AGM-tetherin AgeI forward and BamHI reverse primers and 
subcloned into pQCXIP. After cloning the AGM-tetherin, the HA-epitope was inserted in 
its ectodomain by site-directed mutagenesis. The HA-rhesus tetherin cytoplasmic tail 
point mutants in pCGCG were also generated by site-directed mutagenesis. All the 
primers used for PCR amplification and HA-tagging of the tetherin constructs are listed 
in table 2.1. 
2.1.3   Nef and Vpu plasmids 
Both SIVmac239-Nef and HIV-1 NL4-3 Vpu (gifts from Dr. Ruth Serra-Moreno, Texas 
Tech University, Lubbock, TX) were subcloned into a bicistronic expression vector 
pCGCG using the XbaI and MluI as restriction sites. The pCGCG bicistronic construct is 
transcriptionally linked to  GFP via an IRES.112  
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2.1.4   Viral envelope plasmids 
The envelope genes from squirrel monkey retrovirus (SMRV; Accession M23385), feline 
RD114 virus (Accession AB705392), Baboon endogenous retrovirus (BaEV; Accession 
AB979448.1), Reticuloendotheliosis virus (REV; Accession AAW57301) and simian 
retrovirus serotypes 1 (Accession M11841), 2 Accession M16605), 4 (Accession 
ADC33202) and 5/Y (Accession AB611707) were commercially synthesized by 
ThermoFisher Scientific GeneArt Gene Synthesis and Services. All these viral envelopes 
were amplified by PCR and subcloned into the pCGCG vector using XbaI and MluI sites. 
The SRV-3 envelope expression plasmid (pTMO) was generously provided by Dr. Eric 
Hunter, Emory Centre for AIDS Research at the Emory University, Atlanta, GA.172 The 
SRV-3 env was amplified using SRV-3 env-specific XbaI forward and MluI reverse 
primers and subsequently cloned into pCGCG vector. A tagged version of SRV-3 env in 
pCGCG was also generated by adding a C-terminus Avi epitope using site-directed 
mutagenesis. The untagged SRV-3 env-pCGCG plasmid was used for both single-cycle 
VLP release assay and downregulation assay. The Avi-tagged SRV-3 env-pCGCG 
plasmid was used for the co-immunoprecipitation experiment. The pCGCG-SRV-3 env 
trafficking mutants Y23S, Y35S and L3S/Y23S were generated using round-the-horn-
PCR. The SRV-3 env cytoplasmic tail alanine scanning mutants and the trafficking 
mutant L3S were also commercially synthesized by ThermoFisher Scientific GeneArt 
Gene Synthesis and Services. All of these fragments were subcloned into a truncated 
SRV-3 env-pCGCG vector using PstI and MluI sites. The truncated SRV-3 env-pCGCG 
vector consists of the entire pCGCG vector, the full-length SRV-3 env SU domain and 
the partial extracellular domain of the SRV-3 env TM subunit before the PstI site. The 
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plasmids expressing the Vesicular Stomatitis virus envelope glycoprotein, pVSV-G and 
the ecotropic Murine Leukemia virus envelope glycoprotein was obtained from the 
Clonetech Laboratories. All the primers used for PCR amplification and Avi-tagging of 
the viral envelope constructs are listed in tables 2.2. 
 
2.2 Maintenance of cell-lines 
The Human Embryonic Kidney cells 293T/17 (HEK-293T/17), GP2-293 cells, Vero cells 
and HT1080 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% Penicillin-Streptomycin solution 
and 1% L-Glutamine. All HEK-293T based stable cell-lines expressing HA-tagged 
tetherin orthologues were maintained in DMEM/10% FBS containing 4 µg/ml of 
puromycin. All cell lines were maintained in 37o C incubators with 5% CO2. 
 
2.3 Generation of stable cell lines 
GP2-293 cells were seeded at a density of 5x105 cells per well in 6-well plates for 
transfection. GP2-293 cells are HEK based retroviral packaging cells stably expressing 
the retroviral gag and pol genes. Using the GenJet lipid-based transfection system, these 
cells were transiently cotransfected using 15 µg of pVSV-G and 15 µg of an empty 
vector, pQCXIP only or pQCXIP-HA-tagged tetherin orthologues or rhesus-human 
tetherin reciprocal chimeras/mutants or rhesus tetherin cytoplasmic tail mutants to 
produce VSV-G pseudotyped retroviral particles packaging these vectors. Forty-eight 
hours post-transfection, one milliliter of the infectious cell culture supernatants 
containing VSV-G pseudotyped retroviral particles packaging either pQCXIP vector only 
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or HA-tetherin-pQCXIP were used to transduce HEK-293T/17 cells. The HEK-293T/17 
cells were seeded at a density of 5x105 cells per well in 6-well plates twenty-four hours 
before transduction. Forty-eight hours post-transduction, the stable cell lines were 
selected in DMEM/10% FBS supplemented with 10µg/ml of puromycin and eventually 
grown in DMEM/10% FBS containing 4 µg/ml of puromycin. Stable 293T cell-lines 
expressing rhesus and human tetherin orthologues were gifted by Dr. David T. Evans, 
University of Wisconsin-Madison, Madison, WI.112 
 
2.4 Single-cycle virus-like-particle release (VLPs) assays 
2.4.1 By transient transfections 
All transfections were performed in 6-well plates. 5x105 HEK-293T/17 cells per well 
were seeded twenty-four hours before transfection. Using the GenJet lipid-based 
transfection protocol, HEK-293T/17 cells were cotransfected with 400 ng of pSARM4 
(wild-type SRV-3) or pSARM-eGFP (SRV-3∆env) or SIVmac239-VIEGFP proviral 
plasmid along with 50 ng, 100 ng and 200 ng of either HA-tagged human or rhesus 
tetherin expression constructs to assay for virus restriction. Additionally, 400 ng of 
plasmids expressing either SIVmac Nef or HIV-1 Vpu or pVSV-G or SRV-3 Env were 
expressed in trans to assess their abilities to rescue viral release.  A total of 1 µg of DNA 
was transfected in each well. The total amount of DNA was normalized by the addition of 
an empty vector, pcDNA3.1. Forty-eight hours post-transfections, transfected cells were 
harvested, and virions were pelleted from cultured supernatants. The protocols for the 
harvest of transfected cells and virus-like-particles (VLPs) pelleting are described in 
section 2.5. 
 57 
2.4.2 By stable transfections 
All transfections were performed in 6-well plates using the GenJet lipid-based 
transfection system. For all transfections, the stable 293T cells was seeded at a density of 
5x105 cells per well. Each of the 293T-based stable cell lines were either expressing an 
empty vector (pQCXIP) or the tetherin orthologues from human/cat/dog/squirrel 
monkey/rhesus macaque/AGM/sooty mangabey/pig-tailed macaque/baboon. To 
determine any species-specific differences in the pattern of viral restriction, all the stable 
HEK-293T cells expressing the HA-tagged tetherin orthologues were transfected with 
400 ng of SIVmac239-VIEGFP proviral plasmid to assay for virus restriction. 
Additionally, 400 ng of plasmids expressing either SIVmac Nef or HIV-1 Vpu or SRV-3 
Env were expressed in trans to assess their abilities to rescue viral release. To map the 
domain of interaction between tetherin and SRV-3 envelope glycoprotein, the 293T cells 
stably expressing either HA-tagged human or rhesus tetherin or human-rhesus tetherin 
reciprocal chimeras or an empty vector (pQCXIP) only were transfected with 400ng of 
SIVmac239-VIEGFP proviral plasmid to assess viral restriction. 400 ng of either Nef or 
Vpu or pVSV-G or SRV-3 Env were expressed in trans to assay for their abilities to 
rescue viral release in the presence of the tetherin chimeras. As a control, 293T-based 
empty vector expressing cell line was transfected with SIVmac239-VIEGFP proviral 
plasmid to assess viral release in the absence of any tetherin. For all of the above 
transfections, a total of 1 µg of DNA was transfected in each well. The difference in the 
total amount of DNA was normalized by the addition of an empty vector, pCGCG 
expressing an IRES-driven GFP only. Forty-eight hours post-transfections, transfected 
cells were harvested, and virions were pelleted from cultured supernatants. The protocols 
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for harvesting transfected cells and virus-like-particles (VLPs) pelleting are described 
below in section 2.5. 
 
2.5 Cell harvesting technique   
2.5.1 Pelleting of virus-like-particles (VLPs) 
Two days after transfection, two milliliters of infectious cell culture supernatants 
containing released virions were collected in 15 milliliters conical tubes and centrifuged 
at 3000 rpm for 5 minutes at room temperature for decanting the virus-containing 
supernatants from the cell debris. 1.5 milliliters of the viral supernatants were filtered 
using 0.45 µm sterile filters. Using a 20% sucrose cushion, the virus-like-particles 
(VLPs) were pelleted from the filtered viral supernatants by ultracentrifugation at 35,000 
rpm for one hour at 4o C. The virions were then lysed by resuspending in 100 µls of 2X 
Laemmli buffer. The proteins samples were denatured by boiling for five to ten minutes 
at 99o C and proceeded to SDS-polyacrylamide gel electrophoresis (PAGE). 
 2.5.2 Preparation of cell lysates 
Two days after transfection, the infectious supernatants were removed from the cells, and 
the transfected cells were washed with 500 µl of PBS and lysed in 300 µl of IP lysis 
buffer (Thermo Scientific Pierce) at 4o C for thirty minutes. The cell lysates were then 
cleared from the cell debris by centrifuging at 14,000 rpm for 10 minutes at 4o C. The 
cleared cell lysates were resuspended in 200 µls of 2X Laemmli buffer. The proteins 





The viral pellets (obtained from the section 2.5.1) and cell lysates (obtained from the 
section 2.5.2) were separated on 12% SDS-polyacrylamide gels and transferred to 
polyvinylidene difluoride (PVDF) membranes by the traditional wet protein transfer 
method at 100V for an hour. The membranes were blocked in 5% non-fat milk in PBS for 
two hours at room temperature, and the proteins of interest were probed with the primary 
antibodies overnight at 4o C. SRV-3/MPMV Gag protein p73 and Capsid protein p27 
were probed with anti-MPMV CA rabbit serum (generously provided by Dr. Michaela 
Rumlova, Institute of Organic chemistry and Biochemistry, Academy of Sciences at the 
Czech Republic) at a dilution of 1:500 in 5% non-fat milk in PBS. SIVmac239 Gag 
protein p55 and Capsid protein p27 were detected using mouse monoclonal antibody 55-
2F12 (NIH AIDS Reagent Program, Division of AIDS NIAID) at a dilution of 1:1000 in 
5% non-fat milk in PBS. Following incubation in the primary antibodies, the membranes 
were washed four times with PBS containing 0.05% Triton X-100 for fifteen minutes 
each. The blots were then re-probed with species-specific IgG-HRP-conjugated goat 
secondary antibodies at a dilution of 1:5000 in 5% non-fat milk in PBS for an hour at 
room temperature. Thereafter, the blots were again washed six times with PBS containing 
0.05% Triton X-100 for fifteen minutes each. The cell lysate blot was stripped for twenty 
minutes using Restore western blot stripping buffer (Thermo ScientificTM PierceTM). 
After two additional five minutes washes in PBS/ 0.05% Triton X-100, the membrane 
was again blocked in 5% non-fat milk in PBS for an hour. HA-tagged tetherin protein 
expression was detected using rabbit polyclonal anti-HA-HRP (Thermo ScientificTM 
PierceTM) antibody at a dilution of 1:2500 in 5% non-fat milk in PBS and b-actin 
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expression was probed using mouse monoclonal to beta Actin-HRP conjugated antibody 
(Abcam) at a dilution of 1:5000 in 5% non-fat milk in PBS. Subsequently, the blots were 
treated with ECL western blotting detection reagents, and protein bands were visualized 
using the Biorad ChemiDoc MP imaging system. The viral capsid band intensities in the 
VLP blots were determined using the Image Lab 4.0.1 software program.  
 
2.7 Downregulation assay 
All transfections were performed in 6-well plates using the GenJet lipid-based 
transfection system. Twenty-four hours prior to transfection, 293T cells stably expressing 
either HA-tagged human or rhesus tetherin orthologue or an empty vector (pQCXIP) only 
were seeded at a density of 5x105 cells per well. In order to optimize the amount of DNA 
required to observe cell surface downregulation of human and rhesus tetherin by Vpu and 
Nef respectively, titrations were carried out by transfecting differential inputs (500ng, 1 
µg, 1.5 µg and 2 µg) of pCGCG-based bicistronic constructs expressing either Vpu or 
Nef and an IRES-driven GFP. A similar titration was also carried out by transfecting 
varying amounts (500 ng, 1 µg, 1.5 µg and 2 µg) of pCGCG-SRV-3 env plasmid and 
plasmids expressing pCGCG-based SRV-3 env trafficking mutants and cytoplasmic tail 
alanine scanning mutants to investigate if SRV-3 Env affects cell surface expression of 
rhesus tetherin. As a control for this experiment, the stable cell lines were also transfected 
with an empty vector, pCGCG expressing only GFP via an IRES. A total of 2 µg of DNA 
was used for transfection in each well in this assay. The difference in the total amount of 
DNA was normalized by the addition of an empty vector, pCGCG expressing an IRES-
driven GFP only. Seventy-two hours post-transfection, the cell culture supernatants were 
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removed and the transfected cells were washed with 500 µl of PBS.  The cells were then 
incubated in 500 µl of Cellstripper solution (Corning) for thirty minutes at room 
temperature. The action of the Cellstripper was inhibited by the addition of two milliliters 
of DMEM/10% FBS containing 4 µg/ml of puromycin. The cell suspensions were 
collected and centrifuged at 1500 rpm for five minutes at room temperature. The 
supernatants were removed and the cells were washed with five milliliters of PBS. After 
removing the PBS, the cells were resuspended in 300 µl of PBS, and each of the cell 
samples were stained with 5 µl of mouse anti-HA-IgG-PE conjugated antibody 
(Columbia Biosciences) for an hour at room temperature. Following this, the cells were 
again washed in 300 µl of PBS and fixed in 1% paraformaldehyde PBS. The cells were 
then analyzed using the BDS FACSAriaII SORP flow cytometer, and the results were 
interpreted using FlowJo 8.7.3 software. At first the cell populations were gated for live 
cells using the forward and side scatter properties of the cells. In order to exclude the 
doublets in the analysis, gating was done for single cells using the forward scatter-area 
(FSC-A) and forward scatter-height (FSC-H) on the live cell population. The single, live 
cell population was gated for tetherin-GFP+ cell populations by using PE on the Y-axis 
(denotes tetherin) and FITC-A (denotes GFP) on the X-axis. To determine the ability of 
other simian retroviral envelopes to downregulate the cell surface expression of rhesus 
tetherin, this same assay was also carried out by transfecting the stable 293T cells 
expressing HA-tetherin with pCGCG-based SRV-1, 2, 4, 5 env and SMRV env 
expression constructs. SRV-3 envelope cytoplasmic tail mutants were also tested in the 
similar assay to determine if the ability of SRV-3 envelope to downmodulate rhesus 
tetherin was dependent on the viral envelope trafficking pathway. The remaining cell 
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harvesting procedure, staining techniques, gating strategy and data analysis method are 
same as above. 
 
2.8 Co-immunoprecipitation 
Twenty-four hours prior to transfection, 293T cells stably expressing either an empty 
vector (pQCXIP) or HA-tagged human or rhesus tetherin orthologues were seeded at a 
density of 5x105 cells per well. On the following day, these stable cell-lines were 
transfected with 2-4 µg of Avi-tagged SRV-3 env expression plasmid. Forty-eight hours 
post-transfection, the cell culture supernatants were removed and the transfected cells 
were washed with 300 µl of ice-cold PBS. The cells were lysed in 300 µl of IP lysis 
buffer (Thermo Scientific Pierce) on ice for thirty minutes. The cell lysate was 
centrifuged at 16,000 x g for eight minutes at 4o C to separate the cell debris. 50 µl of the 
cell lysate was removed for verification of protein expression by immunoblotting. 25 µl 
of protein A-Sepharose magnetic beads (New England Biolabs) were added to the 
remaining 250 µl of the cell lysate and incubated for an hour at 4o C on a rotating 
platform. The samples were kept on a magnetic rack, and the supernatants were collected 
into new eppendorf tubes. These samples were incubated with 1 µg of rabbit polyclonal 
anti-BST2 (ThermoFisher Scientific) antibody for an hour at 4o C on a rotating platform. 
After an hour, 25 µl of protein A-Sepharose magnetic beads were added to the protein-
antibody complex, and the incubation was carried out overnight at 4o C on a rotating 
platform. The beads were washed thrice with 500 µl IP lysis buffer and resuspended in 35 
µls of 2X Laemmli buffer. All samples were boiled for five minutes at 95o C and 
proceeded to SDS-PAGE and immunoblotting. The immunoblotting procedure described 
 63 
previously in section 2.6 was repeated here. The expression of SRV-3 Env was detected 
by using mouse monoclonal anti-Avi tag antibody (Avidity) and tetherin expression was 




































Table 2.1: Primers used for site-directed mutagenesis and PCR amplification of tetherin. 















































































































































































































































































































































































































































































































































































































































































































































Table 2.2: Primers used for site-directed mutagenesis and PCR amplification of viral 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.1 MPMV/SRV-3 envelope glycoprotein is the viral determinant in the host-specific 
tetherin resistance 
 The antiviral effector tetherin is targeted by the Vpu protein of HIV-1 and the Nef 
proteins of simian immunodeficiency viruses (SIVs).80,81,112 While the focus has been on 
such complex retroviruses with dedicated tetherin antagonists, it remains unclear as to 
how simple retroviruses, such as those classified as betaretroviruses and 
gammaretroviruses, overcome tetherin-mediated restriction. In order to address this gap 
in knowledge, I first focused on Mason-Pfizer Monkey Virus (MPMV), also known as 
Simian Retrovirus-3 (SRV-3)  
The Type-D simian retroviruses (SRVs) are betaretroviruses that cause 
pathogenesis and immunodeficiency in Asian macaques. SRV-3, more commonly known 
as Mason-Pfizer Monkey Virus (MPMV)) is a prototypical type-D betaretrovirus first 
isolated from the breast carcinoma of female rhesus macaque.173 Previously, the Bieniasz 
laboratory reported that SRV-3/MPMV is sensitive to restriction by human tetherin.92 
However, given that the natural host of SRV-3 is the rhesus macaque and together with 
publishing reports that rhesus macaque tetherin is functional against other retroviruses 
both in vitro and in vivo,112 I hypothesized that SRV-3 must be resistant to rhesus 
macaque tetherin.  
In order to test this hypothesis, I first compared the release of SRV-3 virions in 
the presence of human tetherin and rhesus tetherin. To do this, I transiently cotransfected 
HEK-293T/17 cells (that do not express any endogenous tetherin), with a full length 
SRV-3 proviral plasmid and with increasing doses of plasmids expressing either human 
or rhesus macaque tetherin. Expression of the SRV-3 full-length Gag polyprotein and 
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capsid protein in the cell lysates and the presence of viral capsid protein in the pelleted 
supernatant was visualized by western blots (Figure 3.1A). SRV-3 Gag and CA protein 
expression in the cell lysates remained unaffected in the presence of both human and 
rhesus tetherin orthologues (Figure 3.1B). However, we observed a decrease in SRV-3 
CA protein in the supernatant in the presence of human tetherin but not in the presence of 
rhesus tetherin. This confirmed that human tetherin restricts release of SRV-3; however, 
as I hypothesized, SRV-3 was insensitive to restriction by rhesus macaque tetherin 
(Figure 3.1B). This differential restriction pattern indicated that SRV-3 was specifically 
adapted to the tetherin homolog of its rhesus macaque host, and may have evolved a 
mechanism to counteract restriction by rhesus tetherin.  
Most complex retroviruses actively evade tetherin-mediated restriction by either 
encoding an anti-tetherin factor like SIV Nef or HIV-1 Vpu,80,112 or by deploying their 
envelope glycoprotein (HIV-2).93 Since SRV-3 is a simple retrovirus and does not have 
any accessory genes, I hypothesized that the SRV -3 envelope glycoprotein may 
antagonize rhesus macaque tetherin. To test this hypothesis, I repeated the single-cycle 
VLP release using an SRV-3 proviral plasmid containing a deletion of the env gene and 
asked whether the expression of SRV-3 Env was necessary for the release of SRV-3 
particles in the presence of rhesus macaque tetherin. The envelope glycoprotein of 
Vesicular Stomatitis Virus (VSV-G) does not antagonize rhesus tetherin and was used as 
a negative control.93 HEK-293T/17 cells were also cotransfected with SRV-3∆env 
proviral plasmid and SRV-3 Env or VSV-G in the absence of any tetherin orthologues as 
control to ensure that the viral envelopes were not facilitating a general enhancement in 
the viral release. 
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As expected, the co-expression of VSV-G in trans failed to rescue the release of 
SRV-3∆env virus from either the human or rhesus tetherin orthologues (Figure 3.1C). 
Moreover, the expression of SRV-3 Env in trans did not rescue SRV-3∆env virion 
release in the presence of human tetherin (Figure 3.1C). However, the transient 
expression of the SRV-3 Env rescued SRV-3∆env virus in the presence of rhesus tetherin 
(Figure 3.1C), suggesting that it functions as a host-specific tetherin antagonist. These 
results indicate that SRV-3 is resistant to restriction by rhesus tetherin and overcomes 

















Figure 3.1. SRV-3 envelope glycoprotein is the viral determinant in the host-specific 
tetherin resistance  
(A) Schematic depiction of the method of single-cycle virus-like-particle (VLP) release 
assay. This assay was performed by cotransfecting proviral plasmids (SRV-3 or SRV-
3∆env) and plasmids expressing tetherin antagonist (such as SRV-3 Env), in HEK-293T 
cells expressing tetherin orthologues. The SRV-3 Gag and capsid expression in the cell 
lysates and the presence of viral capsid protein in the pelleted supernatant was visualized by 
western blots.  
(B) Western blot analysis of the transfection of 293T cells with SRV-3 proviral plasmid 
in the presence or the absence of increasing doses of human or rhesus tetherin.  
(C) Western blot analysis of the cotransfection of 293T cells with either full-length SRV-
3 proviral plasmid or the SRV-3∆env and plasmids expressing SRV-3 Env or VSV-G; 
transfection was done either in the presence or the absence of increasing doses of human 
or rhesus tetherin.  
 In figures (B) and (C)- the SRV-3 Gag and capsid expressions were probed with anti-
MPMV capsid rabbit serum and tetherin expression was probed with rabbit polyclonal 



























Figure 3.1. SRV-3 envelope glycoprotein is the viral determinant in the host-specific 





3.2 SRV-3 envelope rescues a heterologous virus from rhesus tetherin 
To determine whether SRV-3 Env is sufficient to antagonize rhesus tetherin, I 
next asked whether SRV-3 Env is able to rescue an unrelated virus from rhesus tetherin. 
To do this, I took advantage of another retrovirus found in rhesus macaques, the Simian 
Immunodeficiency Virus (SIVmac). SIVmac is a primate lentivirus and encodes an 
accessory protein, Nef, that counteracts restriction by rhesus tetherin.112 Additionally, 
some reports suggest SIVmac Env protein may have residual anti-tetherin activity.158,159  
I therefore asked whether SRV-3 Env expression in trans is able to rescue a nef- 
and env- deleted variant of SIVmac239 isolate (SIVmac239∆nef∆env) from rhesus 
tetherin. To test this, I performed the single-cycle VLP release assay by cotransfecting 
293T cells with SIVmac239∆nef∆env proviral plasmid and plasmids expressing the SRV-
3 Env, SIVmac239Nef, HIV-1 Vpu, or VSV-G, in the presence and absence of human 
and rhesus tetherin orthologues. SIV Nef and HIV-1 Vpu antagonize rhesus and human 
tetherin, respectively, and were used as positive controls.112 Forty-eight hours post-
transfection, transfected cells were harvested and lysed, and virions were pelleted from 
cultured supernatants by ultracentrifugation. Expression of the SIVmac239 Gag 
polyprotein and capsid protein in the cell lysate and the presence of the viral capsid 
expression in the pellets were visualized by western blots.  
In the absence of the expression of any of the tetherin antagonists, the release of 
SIVmac239∆nef∆env virions was inhibited by both human and rhesus tetherin (Figure 
3.2). VSV-G did not rescue the virus in the presence of either of the tetherin orthologues 
(Figure 3.2). Consistent with previous studies, the expression of HIV-1 Vpu in trans 
rescued SIVmac239∆nef∆env virus from human tetherin, but not from rhesus tetherin. In 
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contrast, SIVmac Nef is known to antagonize rhesus tetherin and not human tetherin; as 
expected, co-expression of SIVmac Nef rescued virion release in the presence of rhesus 
tetherin but not from human tetherin. Similar to SIVmac Nef, co-expression of SRV-3 
Env rescued the release of SIVmac239∆nef∆env virions from rhesus tetherin, but not 
from human tetherin. These data strongly suggest that: 1) the SRV-3 envelope is a very 
potent tetherin antagonist, and that its anti-tetherin function is not specific to the release 
of SRV-3 only, and 2) the expression of SRV-3 envelope alone is sufficient to antagonize 
























Figure 3.2. SRV-3 envelope rescues a heterologous virus from rhesus tetherin  
Western blots showing the results of cotransfection of 293T-based stable cell lines 
expressing either human tetherin or rhesus tetherin, with SIVmac239∆nef∆env proviral 
plasmid and plasmids expressing SIVmac Nef, HIV-1 Vpu, SRV-3 Env, or VSV-G. The 
SIV Gag and capsid expressions were probed with anti-SIVmac p27 monoclonal 
antibody and tetherin expression was probed with rabbit polyclonal anti-BST2 antibody. 









3.3 SRV-3 Env antagonizes Old world monkey (OWM) tetherin orthologues 
We next asked whether SRV-3 Env was able to antagonize restriction by other 
Old World monkey (OWM) tetherin orthologues. To examine the ability of SRV-3 Env 
to antagonize other OWM tetherin orthologues, we used HEK-293T cells stably 
expressing an ectodomain HA-tagged OWM tetherin orthologues from African-green 
monkey, sooty mangabey and pig-tailed macaques. These cells were cotransfected with 
SIVmac239∆nef∆env proviral plasmid in the presence of either SRV-3 Env or 
SIVmac239 Nef or HIV-1 Vpu or VSV-G. In contrast, HIV-1 Vpu did not rescue the 
virus from any of these OWM tetherins, suggesting that HIV-1 Vpu lacks tetherin-
antagonism against the OWM tetherin orthologues. VSV-G also failed to counteract 
OWM tetherins due to the lack of anti-tetherin function (Figure 3.3B). However, similar 
to SIVmac239 Nef, SRV-3 Env expression in trans rescued SIVmac239∆nef∆env virus 
from each of the OWM tetherin orthologues that we have tested (Figure 3.3A). Thus, 
these observations indicate that the SRV-3 envelope glycoprotein appears to function as 























Figure 3.3. SRV-3 Env antagonizes all the OWM tetherin orthologues  
(A) Western blot analysis to show the results for the transfection of stable cell lines 
expressing either pig-tailed macaque (PT) or African-green monkey (AGM) or sooty 
mangabey (SMM) tetherin orthologues, with SIVmac239∆nef∆env proviral plasmid and 
SIVmac Nef or SRV-3 envelope expression constructs.  
(B) Western blot analysis to show the results for the transfection of the 293T-based stably 
expressing OWM tetherins with SIVmac239∆nef∆env proviral plasmid and plasmids 
expressing HIV-1 Vpu or VSV-G. 
In both figures (A) and (B), the SIV Gag and capsid expressions were probed with anti-
SIVmac p27 monoclonal antibody and tetherin expression was probed with rabbit 
polyclonal anti-BST2 antibody. Beta-actin was used as a loading control for the lysates. 
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3.4 The cytoplasmic tail of tetherin influences sensitivity to SRV-3 envelope 
To map the determinants of differential tetherin-antagonism by the SRV-3 
envelope, I used a panel of 293T-based cell lines that were engineered to stably express 
HA-tagged human and rhesus tetherin reciprocal chimeras. The reciprocal tetherin 
chimeras were constructed by either swapping the cytoplasmic tail or the transmembrane 
domain of rhesus tetherin in human tetherin and vice versa.112 These stable cell lines were 
cotransfected with SIVmac239∆nef∆env proviral plasmid and differential inputs of either 
SRV-3 env, or SIVmac239 nef, or HIV-1 vpu, or VSV-g expression constructs. In the 
absence of any tetherin antagonist, the release of SIVmac239∆nef∆env virus was strongly 
inhibited by both wild-type rhesus tetherin and wild-type human tetherin and by all of the 
human-rhesus chimeric tetherin proteins (Figures 3.4A and 3.4B). As positive controls, 
we used SIVmac Nef and HIV-1 Vpu. Previous studies have shown that Vpu antagonizes 
human tetherin by interacting with the transmembrane domain of human tetherin while 
SIVmac239 Nef counteracts rhesus tetherin by targeting the cytoplasmic tail of rhesus 
tetherin 112. Consistent with these findings, we also observed that Vpu was able to rescue 
SIVmac239∆nef∆env virus in the presence of those tetherin chimeras, that encode the 
human tetherin transmembrane domain (Figure 3.4A). We further observed that 
SIVmac239 Nef was able to promote virion release in the presence of only those tetherin 
chimeras that contained the rhesus tetherin cytoplasmic tail (Figure 3.4A).  
SRV-3 Env was unable to rescue virions in the presence of the Hu-CT and Rh-
TM tetherin chimeras, both of which encode the cytoplasmic tail of human tetherin 
(Figure 3.4B). In contrast, SRV-3 Env rescued SIVmac239∆nef∆env virions in the 
presence of both the Hu-TM and Rh-CT tetherin chimeras, both of which encode the 
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cytoplasmic tail of rhesus tetherin. These findings indicate that the cytoplasmic tail of 
rhesus tetherin is the key determinant of SRV-3 envelope-mediated tetherin-antagonism.  
I next sought to identify specific residues in the rhesus tetherin cytoplasmic tail 
that account for the differential restriction pattern. Comparative sequence analysis of 
human and rhesus tetherin cytoplasmic tails revealed a difference of eleven amino acids, 
including a segment of five consecutive residues, 14GDIWK18, found in the rhesus 
tetherin cytoplasmic tail but absent from the human tetherin (Figure 3.4D). Previous 
study by Jia et al., has shown that the SIVmac Nef targets these five residues on rhesus 
tetherin cytoplasmic tail.112 Given the similar patterns of antagonism displayed by the 
SIVmac Nef and SRV-3 envelope, we hypothesize that these same residues may affect 
recognition by SRV-3 envelope. To test this, we performed the single-cycle VLP release 
assay using cell lines engineered to stably express human and rhesus tetherin reciprocal 
mutants (Hu-GDIWK and Rh∆GDIWK) (Figure 3.4D). Similar to SIVmac Nef, SRV-3 
Env was unable to rescue virion release in the presence of the rhesus tetherin mutant 
lacking these five residues (Rh∆GDIWK). In contrast, SRV-3 Env rescued virion release 
from the human tetherin mutant (Hu-GDIWK) in which these five residues have been 
restored (Figure 3.4E). These findings reveal that the binding sites for SIVmac Nef and 
SRV-3 Env overlap and involve some or all of the residues from position 14 to 18 in the 






Figure 3.4: The cytoplasmic tail of tetherin influences sensitivity to SRV-3 envelope 
(A) HA-tagged human (highlighted in blue)-rhesus (highlighted in red) tetherin reciprocal 
chimeras were constructed by swapping the transmembrane domain and cytoplasmic tail 
of rhesus tetherin in human tetherin and vice versa. 293T based stable cell-lines were 
generated for stably expressing these tetherin chimeras. Western blots showing the results 
of cotransfection of the stable cell lines {expressing either rhesus tetherin or rhesus 
tetherin with human tetherin transmembrane domain (Hu-TM) or human tetherin with 
rhesus tetherin cytoplasmic tail (Rh-CT)} with SIVmac239∆nef∆env proviral plasmid 
and plasmids expressing SIVmac Nef, HIV-1 Vpu, SRV-3 Env, or VSV-G.  
(B) Western blots showing the results of cotransfection of stable cell lines {expressing 
either human tetherin or human tetherin with rhesus tetherin transmembrane domain (Rh-
TM) or rhesus tetherin with human tetherin cytoplasmic tail (Hu-CT)} with 
SIVmac239∆nef∆env proviral plasmid and plasmids expressing SIVmac Nef, HIV-1 
Vpu, SRV-3 Env, or VSV-G.  
 (C) Western blots showing the results of cotransfection of an empty vector expressing 
cell lines, with SIVmac239∆nef∆env proviral plasmid and either SIVmac Nef, or HIV-1 
Vpu, or SRV-3 Env, or VSV-G. 
(D) Sequence alignment showing the amino acid differences in the cytoplasmic tail of 
human and rhesus tetherin. Dashes indicate deletions; amino acid differences are 
highlighted in red. Rhesus and human tetherin mutants were created by introducing 
14GDIWK18 motif in human tetherin CT (Hu+GDIWK) and deleting the same from the 
rhesus tetherin CT (Rh∆GDIWK).  
(E) Western blot analysis showing the results of cotransfection of stable cell lines 
expressing the rhesus and human tetherin reciprocal mutants, with SIVmac239∆nef∆env 
proviral plasmid and increasing inputs of either SRV-3 Env or SIVmac Nef expression 
constructs. The differences in the restriction patterns of the tetherin mutants in the 
presence of SRV-3 envelope are highlighted by the red boxes. 
In figures (A), (B), (C) and (E), the SIV Gag and capsid expressions were probed with 
anti-SIVmac p27 monoclonal antibody and tetherin expression was probed with rabbit 







































3.5 SRV-3 envelope glycoprotein physically associates with rhesus tetherin 
To determine whether antagonism by SRV-3 envelope involves a direct physical 
interaction with tetherin, we performed a co-immunoprecipitation assay. Tetherin was 
immunoprecipitated from the cell lysates using a polyclonal anti-BST2 antibody. We 
observed that SRV-3 Env was efficiently pulled down upon immunoprecipitation of the 
wild-type rhesus tetherin (Figure 3.5). Additionally, SRV-3 Env was also co-
immunoprecipitated with the human tetherin mutant (Hu-GDIWK) that had the 
14GDIWK18 residues of rhesus tetherin in its cytoplasmic tail. However, as expected there 
was no detectable physical association between SRV-3 Env and the wild-type human 
tetherin or the rhesus tetherin mutant, Rh∆GDIWK (Figure 3.5). Therefore, this data 
confirms that the SRV-3 Env physically interacts with rhesus tetherin, and that the 
interaction likely involves the 14GDIWK18 motif in the cytoplasmic tail of rhesus tetherin.  
 
3.6 The envelope glycoproteins of simian retroviruses (SRVs) are tetherin 
antagonists 
SRV-3 is a prototypical type-D retrovirus and this group consists of several other 
simian retroviruses (SRV-1, -2, -4 and -5) having similar genomes and overlapping host 
ranges.13 Hence, we wanted to ask if the observed anti-tetherin function of the SRV-3 
envelope was conserved among the envelope glycoproteins of these related viruses. To 
address this question, I tested the envelope glycoproteins of SRV-1, -2, -4 and -5 in the 
single cycle-VLP release assay for the ability to rescue SIVmac239∆nef∆env virion 
release in the presence of the human and rhesus tetherin orthologues. Like SIVmac Nef, 
the SRV envelope glycoproteins that I have tested, exhibited similar pattern of tetherin-
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antagonism against rhesus tetherin. The transient expression of the envelope 
glycoproteins from SRV-1 through SRV-5 rescued SIVmac239∆nef∆env virion release in 
the presence of rhesus tetherin but not in the presence of human tetherin (Figure 3.6A). 
Thus, these reveal that tetherin-antagonism is a conserved trait of the envelope 






















Figure 3.5. SRV-3 envelope glycoprotein physically associates with rhesus tetherin 
Co-immunoprecipitation assay of stable cell lines expressing either an empty vector or 
human and rhesus tetherin orthologues or human and rhesus tetherin reciprocal mutants 
that were transfected with plasmid expressing a C-terminal Avi-tagged SRV-3 env. 
Tetherin was immunoprecipitated with an anti-BST2 polyclonal antibody. The 
immunoprecipitation was analyzed by western blotting. The expression of SRV-3 
envelope and tetherin in the whole cell lysates were visualized by western blotting. SRV-
3 envelope expression was probed with anti-Avi tag antibody and tetherin expression was 









Figure 3.6. The envelope glycoproteins of simian retroviruses (SRVs) are tetherin 
antagonists 
(A) Western blot analysis showing the results of cotransfection of 293T-based stable cell 
lines expressing rhesus or human tetherin orthologues, with SIVmac239∆nef∆env 
proviral plasmid and differential doses of either SRV-3 Env or SIVmac Nef.  
(B) Western blot analysis showing the results of cotransfection of the human and rhesus 
tetherin expressing stable cell lines with SIVmac239∆nef∆env proviral plasmid and 
increasing inputs of either HIV-1 Vpu or VSV-G.  
 (C) Western blots showing the results of cotransfection of an empty control cell lines, 
with SIVmac239∆nef∆env proviral plasmid and either SIVmac nef, or HIV-1 vpu, or 
VSV-g, or SRV-1 through SRV-5 env expression constructs. 
In figures (A), (B) and (C), the SIV Gag and capsid protein expressions were probed with 
anti-SIVmac p27 monoclonal antibody and tetherin expression was probed with rabbit 
























Figure 3.6: The envelope glycoproteins of simian retroviruses (SRVs) are tetherin 
antagonists. Continued.  
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3.7 Simian retroviral envelopes downmodulate rhesus tetherin from the cell surface 
We next wanted to investigate the tetherin- evasion mechanism employed by the 
SRV envelopes to counteract restriction by rhesus tetherin. Previously, the tetherin 
antagonists of complex retroviruses like SIVmac Nef, HIV-1 Vpu and HIV-2 Env were 
shown to downregulate their respective host tetherins from the cell surface.93,112,133 To 
determine if SRV Envs affected the cell-surface levels of rhesus tetherin, we used a two-
color flow cytometry assay.112 At first, a series of titrations were performed by using cell 
lines that were engineered to stably express either the human or the rhesus tetherin having 
an ectodomain HA-epitope. These stable cell lines were transfected with differential 
inputs of vector expressing tetherin antagonist (either SIVmac Nef or HIV-1 Vpu or 
SRV-3 Env) and an IRES-driven GFP. Since SIVmac Nef and HIV-1 Vpu were used as 
controls against rhesus and human tetherin respectively, we wanted to optimize the 
amount of DNA required to observe cell surface downregulation of human and rhesus 
tetherin by HIV-1 Vpu and SIVmac Nef respectively. The transfected cells were stained 
for cell-surface tetherin expression and analyzed by flow cytometry. At first, the cell 
populations were gated for live cells using the forward and side scatter properties of the 
cells. In order to exclude the doublets in the analysis, gating was done for single cells 
using the forward scatter-area (FSC-A) and forward scatter-height (FSC-H) on the live 
cell population. The single, live cell population was gated for tetherin-GFP+ cell 
populations indicated by PE on the Y-axis and FIT-C on the X-axis (Figure 3.7A). The 
degree of cell surface downregulation of tetherin was determined by the median 
fluorescence intensity (MFI) values (Table 3.1). We noticed that an optimal amount of 
500ng of Nef and 1 µg of Vpu was necessary to observe a 40% reduction in the cell 
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surface expression of rhesus and human tetherin respectively (Figure 3.7B and Table 
3.1). In contrast, we observed that increasing inputs of SRV-3 Env resulted in an increase 
in the magnitude of cell surface downregulation of rhesus tetherin (Figure 3.7C and Table 
3.1). As expected, the expression of SRV-3 envelope did not reduce cell surface levels of 
human tetherin. 
We conducted the same assay by transfecting the cells expressing either an 
ectodomain HA-tagged human tetherin or rhesus tetherin, with bicistronic constructs 
expressing the envelope glycoproteins of SRV-1, -2, -3, -4 and -5 and an IRES-driven 
GFP. We also tested the envelope glycoprotein of SMRV (a new world monkey SRV) for 
its ability to downmodulate tetherin from the cell surface. Although the SRV envelopes 
did not affect the cell surface expression of human tetherin, they did result in a 30%-60% 
reduction in the cell surface levels of rhesus tetherin (Figure 3.7D and Table 3.2). 
Therefore, our data suggest that in the absence of a dedicated tetherin antagonist, the 
envelope glycoproteins of simian retroviruses have evolved to evade tetherin-mediated 
restriction by reducing the cell surface rhesus tetherin levels.  
 
3.8 The ability of SRV-3 envelope to downmodulate cell surface expression of rhesus 
tetherin is independent of its trafficking pathway 
In 2009, Tortorec et al., showed that the endocytosis motif GYxxq in the 
cytoplasmic tail of HIV-2 Env was necessary for reducing cell surface levels of human 
tetherin and sequestering it within the TGN.93 SRV-3 Env has a dileucine and a tyrosine-
motifs in its cytoplasmic tail, which were shown to play critical roles in envelope 
trafficking.33 The leucine at position 3 in the SRV-3 Env cytoplasmic tail was reported to 
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be necessary for the anterograde transport and a tyrosine at position 23 in the cytoplasmic 
tail of SRV-3 Env was critical for the recycling of the SRV-3 envelope glycoprotein.33 
Mutations of both leucine and tyrosine to serine alter the trafficking pathway of the SRV-
3 envelope glycoproteins. The cytoplasmic tail of SRV-3 envelope also harbors a second 
tyrosine at position 35 that was shown to be indispensable for Env trafficking.33 Hence, I 
wanted to investigate whether the mutations in the dileucine and the tyrosine-motifs in 
the SRV-3 Env cytoplasmic tail abrogated its ability to downmodulate rhesus tetherin 
from the cell surface. I performed the two-color flow cytometry assay by transfecting 
stable cell lines engineered to express either an ectodomain-HA-tagged human or rhesus 
tetherin orthologue, with bicistronic plasmids expressing either the wild-type SRV-3 
envelope or the SRV-3 envelope cytoplasmic tail trafficking mutants (L3S or Y23S or 
Y35S or L3S/Y23S) and an IRES-driven GFP. The stable cell lines were also 
cotransfected with bicistronic constructs expressing either SIVmac Nef or HIV-1 Vpu 
and an IRES-driven GFP to serve as reciprocal controls against rhesus and human 
tetherin respectively. The transfected cells were stained for cell-surface tetherin 
expression and the degree of cell surface downregulation of tetherin was determined by 
the median fluorescence intensity (MFI) values (Table 3.3).  Interestingly, mutating the 
SRV-3 envelope trafficking signals in its cytoplasmic tail did not abrogate the ability of 
SRV-3 envelope to downregulate rhesus tetherin from the cell surface (Figure 3.8B). The 
SRV-3 envelope cytoplasmic tail mutants L3S and Y23S mutants resulted in a 30% 
reduction of cell surface rhesus tetherin levels while the Y35S and L3S/Y23S mutants 
significantly downregulated cell surface rhesus tetherin levels to approximately 50% 
(Table 3.3). However, similar to the wild-type SRV-3 envelope, the SRV-3 envelope 
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trafficking mutants had no impact on the cell surface expression of human tetherin 
(Figure 3.8B and Table 3.3). The sequences of all the SRV-3 Env CT trafficking mutants 
used in this study are listed in Figure 3.8A. 
Since mutations in the SRV-3 envelope trafficking signals did not affect its ability 
to downregulate cell surface rhesus tetherin levels, I conducted alanine scanning 
mutagenesis to identify the residues in the SRV-3 Env cytoplasmic tail that might be 
critical for downregulating the cell surface expression of rhesus tetherin. I did a 
comparative sequence analysis of the cytoplasmic tails of the different simian retroviral 
envelope glycoproteins and found some conserved motifs within them. These include the 
dileucine motif (L3M4), a tyrosine-based motif at position 23 (Y23HRL26), the conserved 
acidic patch (E27QED30) and a second tyrosine-based motif at position 35 (Y35LTLT39). 
These individual motifs in the cytoplasmic tail of SRV-3 envelope were replaced with 
stretches of alanines: L3M4 were mutated to A3A4, Y23HRL26 were mutated to A23-A26, 
Y35LTLT39 were mutated to A35-A39 and E27QED30 were mutated to A27-A30. The 
sequences of these SRV-3 Env CT alanine scanning mutants are listed in Figure 3.8C. 
The two-color flow cytometry assay was carried out by transfecting the HA-tagged 
human and rhesus tetherin expressing stable cell lines with plasmids expressing either the 
wild-type SRV-3 envelope or the SRV-3 envelope cytoplasmic tail alanine scanning 
mutants. The stable cell lines were also cotransfected with plasmids expressing either 
SIVmac Nef or HIV-1 Vpu to serve as reciprocal controls against rhesus and human 
tetherin respectively. The transfected cells were stained for cell-surface tetherin 
expression and the degree of cell surface downregulation of tetherin was determined by 
the median fluorescence intensity (MFI) values (Table 3.4).   
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Similar to the wild-type SRV-3 envelope, most of the SRV-3 envelope 
cytoplasmic tail alanine scanning mutants reduced cell surface rhesus tetherin levels by 
approximately 40% (Figure 3.8D and Table 3.4). In contrast, the SRV-3 Env CT alanine 
scanning mutants had little or no impact on the cell surface levels of human tetherin 
(Figures 3.8D and Tables 3.4). Overall the data from this assay indicate that the ability of 
SRV-3 envelope to downregulate cell surface expression of rhesus tetherin is not 
dependent on the known trafficking mutants in the cytoplasmic tail of the envelope. This 
observation also raises the possibility that the interaction between rhesus tetherin and 
SRV-3 envelope might take place within the secretory pathway before both the proteins 
reach the cell surface. It is possible that instead of depleting rhesus tetherin from the cell 
surface, the SRV-3 Env might be actually sequestering newly-synthesized tetherin in the 
trans-Golgi network (TGN) and preventing it from reaching the cell surface. Further 














Figure 3.7. Simian retroviral envelopes downmodulate rhesus tetherin from the cell 
surface 
(A) Representative dot plots showing the gating strategy used to analyze flow cytometry 
data. The cell populations were gated for live cells using the forward and side scatter 
properties of the cells. In order to exclude the doublets in the analysis, gating was done 
for single cells using the forward scatter-area (FSC-A) and forward scatter-height (FSC-
H) on the live cell population. The single, live cell population was gated for tetherin-
GFP+ cell populations indicated by PE on the Y-axis and FIT-C on the X-axis.  
(B) A two-color flow cytometry assay was performed to optimize the amount of Nef and 
Vpu plasmids required to observe downregulation of cell surface levels of rhesus and 
human tetherin. Stable 293T cells expressing an ectodomain HA-tag rhesus or human 
tetherin were transfected with differential inputs (500 ng, 1 µg, 1.5 µg and 2 µg) of vector 
expressing tetherin antagonist (either SIVmac Nef or HIV-1 Vpu), that has an IRES-
driven GFP. Cells were also transfected with an empty vector (lacking any tetherin 
antagonist) as a control. Seventy-two hours after transfection, the cells were stained for 
cell surface tetherin expression with an anti-HA-IgG-PE conjugated antibody and 
analyzed using flow cytometry. X-axis represents tetherin and Y-axis denotes tetherin-
antagonist-GFP (SIVmac Nef or HIV-1 Vpu). The median fluorescence intensity values 
(MFI) and percentage values of tetherin-GFP+ cells are shown in table 3.1. 
(C) Flow cytometry analysis of the transfections of stable cell lines expressing either HA-
tagged rhesus or human tetherin orthologues, with increasing inputs (500 ng, 1 µg, 1.5 µg 
and 2 µg) of bicistronic plasmids expressing SRV-3 envelope and an IRES-driven GFP. 
X-axis represents tetherin and Y-axis denotes tetherin-antagonist-GFP (SRV-3). The 
median fluorescence intensity values (MFI) and percentage values of tetherin-GFP+ cells 
are shown in table 3.1. 
(D) Flow cytometry analysis of the transfections of stable cells expressing either HA-
tagged rhesus or human tetherin orthologues, with 2 µg of bicistronic plasmids 
expressing simian retroviral envelope glycoproteins and an IRES-driven GFP. Two days 
after transfection, the cells were stained for cell surface tetherin expression with an anti-
HA-IgG-PE conjugated antibody and analyzed using flow cytometry. X-axis represents 
tetherin and Y-axis denotes tetherin-antagonist-GFP. The median fluorescence intensity 
































Table 3.1. The median fluorescence intensity values (MFI) and percentage values of 
tetherin-GFP+ cells for analyzing the downregulation of cell surface tetherin expressions 

















MFI % change in MFI MFI % change in MFI
Vector 187 100.0 249 100.0
Vpu
500ngs 144 77.0 216 86.7
1.0µg 118 63.1 207 83.1
1.5µgs 167 89.3 218 87.6
2.0µgs 155 82.9 228 91.6
Nef
500ngs 146 78.1 148 59.4
1.0µg 135 72.2 166 66.7
1.5µgs 167 89.3 194 77.9
2.0µgs 187 100.0 203 81.5
SRV-3 Env
500ngs 188 100.5 190 76.3
1.0µg 158 84.5 160 64.3
1.5µgs 154 82.4 137 55.0
2.0µgs 156 83.4 121 48.6
Human tetherin Rhesus tetherin
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Table 3.2. The median fluorescence intensity values (MFI) and percentage values of 
tetherin-GFP+ cells for analyzing the downregulation of cell surface tetherin expressions 
































MFI % change in MFI MFI % change in MFI
Vector 1121 100.0 893 100.0
Vpu 684 61.0 709 79.4
Nef 1236 110.3 506 56.7
SMRV Env 1379 123.0 595 66.6
SRV-1 Env 1686 150.4 579 64.8
SRV-2 Env 1466 130.8 435 48.7
SRV-3 Env 996 88.8 336 37.6
SRV-4 Env 1422 126.9 583 65.3
SRV-5 Env 1472 131.3 540 60.5
Human tetherin Rhesus tetherin
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Figure 3.8. The ability of SRV-3 envelope to downmodulate cell surface expression 
of rhesus tetherin is independent of its trafficking pathway 
(A) Schematic showing the sequences of the SRV-3 envelope trafficking mutants. The 
amino acid changes are highlighted in red and the amino acid position is highlighted with 
a green box. 
(B) A two-color flow cytometry assay was conducted with SRV-3 envelope trafficking 
mutants to investigate if the mutations in the trafficking motifs impede the ability of the 
SRV-3 envelope to downregulate the cell surface levels of rhesus tetherin. Stable cells 
expressing HA-tagged rhesus or human tetherin orthologues were transfected with 2 µg 
of bicistronic plasmids expressing SRV-3 trafficking mutants and an IRES-driven GFP. 
SIVmac Nef and HIV-1 Vpu were used as controls against rhesus and human tetherin 
respectively. Two days after transfection, the cells were stained for cell surface tetherin 
expression with an anti-HA-IgG-PE conjugated antibody and analyzed using flow 
cytometry. X-axis represents tetherin and Y-axis represents tetherin-antagonist-GFP. The 
median fluorescence intensity values (MFI) and percentage values of tetherin-GFP+ cells 
are shown in table 3.3. 
(C) Schematic showing the sequences of the SRV-3 envelope cytoplasmic tail mutants 
used in the alanine scanning mutagenesis study. The amino acid changes are highlighted 
in red. 
(D) Flow cytometry analysis of transfections of cells stably expressing HA-tagged rhesus 
or human tetherin orthologues, with the SRV-3 envelope cytoplasmic tail alanine 
scanning mutants. The cells were stained with an anti-HA-IgG-PE conjugated antibody 
for cell surface tetherin expression. The X-axis represents tetherin and Y-axis represents 
tetherin-antagonist-GFP. The median fluorescence intensity values (MFI) and percentage 






























Figure 3.8. The ability of SRV-3 envelope to downmodulate cell surface expression 









Figure 3.8. The ability of SRV-3 envelope to downmodulate cell surface expression 







Table 3.3. The median fluorescence intensity values (MFI) and percentage values of 
tetherin-GFP+ cells for analyzing the downregulation of cell surface tetherin expressions 




















MFI % change in MFI MFI % change in MFI
Vector 360 100.0 291 100.0
Vpu 268 74.4 394 135.4
Nef 318 88.3 192 66.0
WT SRV-3 Env 543 150.8 196 67.4
Y23S 492 136.7 212 72.9
Y35S 381 105.8 165 56.7
L3S 366 101.7 207 71.1
L3S/Y23S 455 126.4 145 49.8
Human tetherin Rhesus tetherin
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Table 3.4. The median fluorescence intensity values (MFI) and percentage values of 
tetherin-GFP+ cells for analyzing the downregulation of cell surface tetherin expressions 



















MFI % change in MFI MFI % change in MFI
Vector 360 100.0 291 100.0
Vpu 268 74.4 394 135.4
Nef 318 88.3 192 66.0
WT SRV-3 Env 543 150.8 196 67.4
A3A4 435 120.8 182 62.5
A23-A26 268 74.4 180 61.9
A27-A30 373 103.6 180 61.9
A35-A39 406 112.8 170 58.4
Human tetherin Rhesus tetherin
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3.9 SRV-3 envelope trafficking mutants affect viral release in the presence of 
tetherin 
Since the SRV-3 Env trafficking mutants and the alanine scanning mutants did 
not have any impact on the downregulation of cell surface rhesus tetherin levels, I next 
wanted to ask whether these mutants affect the ability of the SRV-3 envelope to rescue 
SIVmac239∆nef∆env virion release from rhesus tetherin. I performed the single-cycle 
VLP release assay by cotransfecting cells stably expressing human and rhesus tetherin 
orthologues, with SIVmac239∆nef∆env proviral plasmid and plasmids expressing either 
the wild-type SRV-3 envelope or the SRV-3 envelope cytoplasmic tail trafficking 
mutants (the SRV-3 Env CT- L3S or Y23S or Y35S or L3S/Y23S) or the SRV-3 
envelope alanine scanning mutants (A3A4 or A23-A26 or A35-A39 or A17-A22 or A27-A30). 
Stable cells expressing an empty vector were transfected with SIVmac239∆nef∆env 
proviral plasmid and all SRV-3 Env CT mutants to ensure that these mutants did not 
cause a general enhancement of viral release in the absence of tetherin. Forty-eight hours 
post-transfection, transfected cells were harvested and lysed and cultured supernatants 
were subjected to ultracentrifugation. Expression of the SIVmac239 Gag polyprotein and 
capsid protein in the cell lysates and the presence of viral capsid protein in the pelleted 
supernatant was visualized by western blots (Figure 3.9).  
Similar to the wild-type SRV-3 envelope, the SRV-3 envelope trafficking mutants 
and the alanine scanning mutants were unable to rescue virions from human tetherin 
(Figure 3.9). This finding is consistent with the data from the downregulation assay in 
which we observed that the mutants also did not affect the cell surface human tetherin 
levels. In contrast, the envelope trafficking mutants failed to completely rescue virions 
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from rhesus tetherin and this was very much evident from the band intensity values 
(Figure 3.9). Compared to the wild-type SRV-3 envelope, mutations of the SRV-3 Env 
CT dileucine motif (LM to A3A4) and the tyrosine motif at position 35 (Y35LTLT39 to 
A35-A39) drastically reduced virion release in the presence of rhesus tetherin. However, 
the other alanine scanning mutants were able to rescue virions from rhesus tetherin but at 
levels lower than the amount of virions released in the absence of any tetherin (Figure 
3.9). It is possible that although these mutants are able to sequester tetherin in the TGN 
but they fail to get translocated to the plasma membrane due to misfolding. The other 
possible explanation is that the SRV-3 envelope mutants might fail to get incorporated 
into the virions which is affecting the ability to rescue virions from rhesus tetherin. 
Overall, the data from this experiment suggested that although the SRV-3 envelope 
cytoplasmic tail mutants did not affect the ability of SRV-3 Env to downmodulate rhesus 
tetherin from the cell surface but they did affect the ability of the viral envelope to rescue 














Figure 3.9. SRV-3 envelope trafficking mutants affect viral release in the presence of 
tetherin 
Western blot analysis showing the results of cotransfection of cells engineered to stably 
express rhesus or human tetherin orthologues, with SIVmac239∆nef∆env proviral 
plasmid and plasmids expressing either wild-type SRV-3 env or SRV-3 env cytoplasmic 
tail mutants. Stable cells expressing an empty vector, were cotransfected with 
SIVmac239∆nef∆env proviral plasmid and plasmids expressing either wild-type SRV-3 
env or SRV-3 env cytoplasmic tail mutants. The SIV Gag and capsid protein expressions 
were probed with anti-SIVmac p27 monoclonal antibody and tetherin expression was 
probed with rabbit polyclonal anti-BST2 antibody. Beta-actin was used as a loading 






3.10 Envelope glycoproteins of retroviruses in the RDR interference supergroup are 
tetherin antagonists 
Simian retroviruses (SRVs) belong to the RD114/D-type (RDR) interference 
supergroup, that consists of multiple pathogenic simple retroviruses from different genera 
infecting diverse hosts like carnivores, OWMs, new world monkeys (NWMs) and even 
birds.12 Apart from simple exogenous retroviruses, this group also includes a number of 
endogenous retroviruses. Although these viruses are unrelated across their gag, pro and 
pol genes, they all share a homologous env gene due to recombination. As a result of 
which, all these viruses use the same receptor (ASCT2) and have significant degree of 
sequence identity in their SU and TM subunits.12 I, therefore, wanted to investigate the 
extent of distribution of tetherin-antagonism among the retroviruses of the RDR 
interference supergroup. I screened a few representative RDR envelope proteins of 
SMRV, BaEV, the feline RD114 and REV for their ability to rescue 
SIVmac239∆env∆nef virions from a panel of tetherin homologs from baboon, squirrel 
monkey, cat and dog. 293T-based cell lines were engineered to express the tetherin 
homologs from baboon, squirrel monkey, cat and dog. These stable cells were 
cotransfected with SIVmac239∆nef∆env proviral plasmid and plasmids expressing either 
SIVmac Nef, or HIV-1 Vpu, or SRV-3 envelope, or envelope glycoproteins of SMRV, 
BaEV, RD114 and REV. As a control, cells stably expressing an empty vector were also 
transfected with SIVmac239∆nef∆env proviral plasmid and plasmids expressing either 
SIVmac Nef or HIV-1 Vpu or SRV-3 envelope or envelope glycoproteins of SMRV, 
BaEV, RD114 and REV to ensure that these expression constructs did not impact viral 
release in the absence of tetherin. Forty-eight hours post-transfection, transfected cells 
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were harvested and lysed and cultured supernatants were subjected to ultracentrifugation. 
Expression of the SIVmac239 Gag polyprotein and capsid protein in the cell lysates and 
the presence of viral capsid protein in the pelleted supernatant was visualized by western 
blots (Figure 3.10). The transient expression of the RDR envelope glycoproteins that we 
have tested were able to promote virion release in the presence of the rhesus macaque, 
baboon, squirrel monkey, cat and dog tetherin homologs (Figure 3.10A-D), indicating 
that the anti-tetherin function is not just restricted to the simian retroviruses of Asian 
macaques, but is actually wide-spread across the simple retroviruses of the RDR 
interference supergroup. It is noteworthy that SIVmac Nef also promoted virion release 
in the presence of baboon, squirrel monkey, cat and dog tetherins, thereby showcasing its 














Figure 3.10. Envelope glycoproteins of retroviruses in the RDR interference 
supergroup are tetherin antagonists 
(A) Western blots showing the results of cotransfection of cell lines stably expressing 
human or rhesus or squirrel monkey tetherin orthologues, with SIVmac239∆nef∆env 
proviral plasmid and plasmids expressing SRV-3 envelope or HIV-1 Vpu or SIVmac Nef 
or envelope glycoproteins of RD114 or BaEV or SMRV.  
(B) Western blots showing the results of cotransfection of 293T-based stable cell lines 
expressing baboon or feline or canine tetherin orthologues, with SIVmac239∆nef∆env 
proviral plasmid and plasmids expressing SRV-3 envelope or HIV-1 Vpu or SIVmac Nef 
or envelope glycoproteins of RD114 or BaEV or SMRV.  
(C) Western blots showing the results of cotransfection of stable cell lines expressing 
human or rhesus or squirrel monkey tetherin orthologues, with SIVmac239∆nef∆env 
proviral plasmid and plasmids expressing SRV-3 envelope or SIVmac Nef or REV 
envelope.  
(D) Western blots showing the results of cotransfection of 293T-based stable cell lines 
expressing baboon or feline or canine tetherin orthologues, with SIVmac239∆nef∆env 
proviral plasmid and plasmids expressing SRV-3 envelope or SIVmac Nef or REV 
envelope. 
(E) Western blots showing the results of cotransfection of an empty vector expressing 
cell line with SIVmac239∆nef∆env proviral plasmid and plasmids expressing the SRV-3 
envelope or HIV-1 Vpu or SIVmac Nef or envelope glycoproteins of RD114 or BaEV or 
SMRV or REV.  
In figures (A) through (E), the SIV Gag and capsid protein expressions were probed with 
anti-SIVmac p27 monoclonal antibody and tetherin expression was probed with rabbit 

















Figure 3.10. Envelope glycoproteins of retroviruses in the RDR interference 















Figure 3.10. Envelope glycoproteins of retroviruses in the RDR interference 
supergroup are tetherin antagonists. Continued. 
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3.11 Mutations of aspartate at position 15 in the cytoplasmic tail of rhesus tetherin 
renders resistance to SRV-3 envelope glycoprotein and Nef 
  Since this study suggested that both SRV-3 Env and SIVmac Nef are able to 
counteract tetherin homologs from rhesus macaque, baboon, squirrel monkey, cat and 
dog, I got interested to examine the determinants in these tetherin homologs that might 
account for this tetherin-antagonism. Comparative sequence analysis revealed the 
presence of an aspartate at position 15, that is highly conserved in the cytoplasmic tail of 
the rhesus macaque, baboon, squirrel monkey, cat and dog tetherin orthologues but 
absent from human tetherin (highlighted in green in Figure 3.11A). I, therefore generated 
293T based stable cell-lines expressing rhesus tetherin point mutants, in which the 
aspartate at position 15 was either deleted or mutated to an alanine. These stable cell-
lines were cotransfected with SIVmac239∆Env∆Nef proviral plasmid and increasing 
inputs of plasmids expressing either wild-type SRV-3 Env or SIVmac Nef or HIV-1 Vpu. 
Consistent with our previous findings, both SIVmac Nef and SRV-3 Env were able to 
promote virion release and antagonize wild-type rhesus tetherin but not human tetherin. 
In contrast, Vpu was able to rescue virion release only in the presence of human tetherin 
and not rhesus tetherin (Figure 3.11B). Mutating the aspartate at position 15 to an alanine 
or deleting it, rendered rhesus tetherin resistant to both SIVmac Nef and SRV-3 envelope 
(Figure 3.11B). The transient expression of SIVmac Nef and SRV-3 envelope were 
unable to rescue virions in the presence of the rhesus tetherin mutants in which the 
aspartate at position 15 is either deleted or substituted with an alanine. In fact, the amount 
of the virions rescued by SRV-3 envelope in the presence of the rhesus tetherin mutants 
were similar to that of the virus restriction observed when SIVmac239∆nef∆env proviral 
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plasmid was transfected in rhesus and human tetherin expressing cells in the absence of 
any tetherin antagonist (Figure 3.11B).  Therefore, this data indicates that the aspartate at 
position 15 in the cytoplasmic tail of rhesus tetherin is critical for the tetherin-antagonism 
of SRV-3 envelope and SIVmac Nef. 
 
 3.12 Tetherin-antagonism is a conserved feature of most gammaretroviral 
envelopes 
The RDR envelope resembles a typical gammaretroviral envelope, that is 
characterized by (i) intersubunit disulfide linkages between the SU and TM subunits and 
(ii) the presence of a canonical immunosuppressive domain (ISD).12 Since this study 
expanded the anti-tetherin function to most RDR envelopes, I got interested to ask 
whether tetherin-antagonism was a conserved feature across all gammaretroviral 
envelope. In order to answer this question, I used the envelope glycoproteins of: (a) the 
most commonly studied exogenous gammaretrovirus, the ecotropic Murine Leukemia 
virus (MLV), (b) an ancient non-RDR endogenous retrovirus from baboons belonging to 
the Fc family called Baboon ERV-Fc (Bab-ERV-Fc) and (c) another endogenous 
gammaretroviral envelope, the HERV-W Syncytin-1. These envelope glycoproteins were 
expressed in trans in the single-cycle VLP release assay to test their ability to rescue 
SIVmac239∆nef∆nef virion release in the presence of human and rhesus tetherin. The 
human and rhesus tetherin expressing stable cell lines were cotransfected with 
SIVmac239∆nef∆env proviral plasmid and differential inputs of plasmids expressing 
either SIVmac Nef, or HERV-W Syncytin-1, or wild-type BabERV-Fc Env or wild-type 
MLV Env. SIVmac Nef was used as a control against rhesus tetherin in this experiment. 
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Forty-eight hours post-transfection, the transfected cells were harvested and the viral 
protein expression in both the cell lysates and pellets were analyzed by immunoblotting. 
None of the viral envelope glycoproteins were able to promote virion release in the 
presence of human tetherin. The Bab-ERV-Fc envelope was sensitive to both human and 
rhesus tetherin orthologues, and failed to rescue virions in the presence of either of the 
tetherin orthologues (Figure 3.12). In contrast, the transient expression of ecotropic MLV 
envelope and HERV-W Syncytin-1 were able to rescue SIVmac239∆nef∆env virions in 
the presence of rhesus tetherin (Figure 3.12). These finding signify that tetherin-
antagonism may be a conserved feature of most gammaretroviral envelopes.  
A previous study has shown that the envelope glycoprotein of a nef-deleted SIV 
upon serial passaging acquired anti-tetherin function against rhesus tetherin and that the 
interaction between the viral Env and rhesus tetherin mapped to the cytoplasmic tails of 
both tetherin and the antagonist.159 Since rhesus tetherin was sensitive to the envelope 
glycoprotein of ecotropic MLV but resistant to the Bab-ERV-Fc envelope, I got curious 
to investigate whether the cytoplasmic tail of the viral envelope determines sensitivity to 
rhesus tetherin. A Bab-ERV-Fc envelope chimera was generated in which the native Bab-
ERV-Fc cytoplasmic tail was swapped with the ecotropic MLV cytoplasmic tail. This 
chimeric envelope construct was used in a gain- or loss- of function approach to 
determine its ability to promote virion release in the presence of tetherin. Similar to the 
wild-type Bab-ERV-Fc Env, the chimeric Bab-ERV-Fc-MLV CT envelope was unable to 
rescue viruses from human tetherin (Figure 3.12). However, when the cytoplasmic tail of 
the Bab-ERV-Fc envelope is substituted with the cytoplasmic tail of the ecotropic MLV 
envelope, the chimeric envelope gained back its ability to antagonize rhesus tetherin and 
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facilitated virion release in the presence of rhesus tetherin (Figure 3.12). The result from 
this experiment suggest that the cytoplasmic tail of MLV is necessary for evading 
tetherin-mediated restriction. However, it is still unclear whether any other domains of 




































Figure 3.11: Mutations of aspartate at position 15 in the cytoplasmic tail of rhesus 
tetherin renders resistance to SRV-3 envelope glycoprotein and Nef 
(A) Alignment of tetherin cytoplasmic tail sequences from human, rhesus macaque, pig-
tailed macaques, sooty mangabey, squirrel monkey, baboon, cat and dog. The conserved 
aspartate at position 15 is highlighted in yellow. Dashes indicate deletions or insertions 
and amino acid differences are highlighted in red. Rhesus tetherin point mutants were 
created by either deleting the aspartate at position 15 or substituting it with an alanine.  
(B) Western Blots showing the results of cotransfection of stable cell lines expressing 
human or rhesus tetherin orthologues or rhesus tetherin mutants, with 
SIVmac239∆nef∆env proviral plasmid and wild-type SRV-3 env expression construct. 
The SIV Gag and capsid protein expressions were probed with anti-SIVmac p27 
monoclonal antibody and tetherin expression was probed with rabbit polyclonal anti-
BST2 antibody. Beta-actin was used as a loading control for the cell lysates. When the 
aspartate at position 15 was either deleted or mutated to an alanine in the rhesus tetherin 
cytoplasmic tail, SRV-3 Env loses its anti-tetherin activity against rhesus tetherin 





















Figure 3.11. Mutations of aspartate at position 15 in the cytoplasmic tail of rhesus 











Figure 3.12. Tetherin-antagonism is a conserved feature of most gammaretroviral 
envelope 
Western blots showing the results of cotransfection of human or rhesus tetherin 
expressing cell lines, with SIVmac239∆nef∆env proviral plasmid and plasmids 
expressing either HERV-W Syncytin-1 or wild-type BabERV-Fc envelope (Env) or wild-
type MLV Env or BabERV-Fc Env/MLV Env chimera. The SIV Gag and capsid protein 
expressions were probed with anti-SIVmac p27 monoclonal antibody and tetherin 
expression was probed with rabbit polyclonal anti-BST2 antibody. Beta-actin was used as 










































During replication in host cells, retroviruses are subjected to restriction by 
numerous host-encoded factors. These cellular factors commonly known as restriction 
factors (RFs), inhibit different steps in the virus life cycle to protect the host cell from 
infection.36 Consequently, most retroviruses especially the primate lentiviruses have 
evolved strategies to counteract inhibition by the restriction factors.43 Retroviruses with 
complex genomes possess additional accessory genes apart from the four canonical 
retroviral genes. Many of these accessory genes encode proteins that assist the viruses to 
evade restriction by the RFs.  
Tetherin forms the exit block during retroviral replication, and unlike all other 
RFs, it restricts the release of a wide range of enveloped viruses in a non-specific manner. 
Tetherin-evasion mechanisms have only been studied in detail for a few viruses: within 
the Retroviridae, the focus has been almost exclusively on HIV and SIV, which encode 
the accessory proteins Vpu and Nef respectively to evade tetherin-mediated 
restriction.80,81,112 Thus, there is a wide knowledge gap encompassing numerous simple 
retroviruses (such as the alpharetroviruses, betaretroviruses and gammaretroviruses) that 
lack obvious accessory genes and are subjected to restriction by a number of RFs 
including tetherin during their replication. In this dissertation, I have sought to find an 
answer to the most obvious and unexplored question: How do simple retroviruses evade 
restriction by tetherin? Additionally, this study has also helped in delineating one of the 
several reasons behind the evolutionary success of the gammaretroviral envelope 
glycoprotein. 
I began addressing the question by using SRV-3/MPMV, which is a prototypical 
type-D betaretrovirus having a very simple genomic organization. This virus was isolated 
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from the breast carcinoma of a juvenile rhesus macaque and was known to cause severe 
immunodeficiency in rhesus macaques.173 Previously, the Bieniasz laboratory reported 
that SRV-3 was sensitive to restriction by human tetherin.92 However, given that the 
natural host of SRV-3 is the rhesus macaque and together with reports that rhesus 
macaque tetherin is functional against other retroviruses both in vitro and in vivo,112 I 
hypothesized that SRV-3 must be resistant to rhesus macaque tetherin. To test this 
hypothesis, I designed a single-cycle virus release assay to determine the sensitivity of 
SRV-3 to rhesus macaque tetherin (Figure 3.1A). Our results confirmed that SRV-3 is 
sensitive to restriction by human tetherin, but also demonstrated that it is resistant to 
restriction by the tetherin of its natural host, the rhesus macaque (Figure 3.1B). The 
species-specific differences observed in the pattern of restriction suggested to me that 
SRV-3 has evolved a mechanism to evade restriction by rhesus macaque tetherin.  
Previous studies have shown that some complex retroviruses (e.g., EIAV, HIV-2 
and SIV from tantalus monkey) and several unrelated viruses (such as Ebola virus and 
HSV-1 and -2) use their envelope glycoproteins as tetherin antagonist.93,101, 158,162,165,166 
Since SRV-3 is a simple retrovirus and does not encode any accessory proteins like SIV 
Nef or HIV-1 Vpu, I hypothesized that the SRV-3 envelope glycoprotein (Env) might 
have an anti-tetherin function. In the presence of human tetherin, the transient expression 
of SRV-3 Env failed to rescue the release of the env-deleted SRV-3 virions (Figure 3.1C). 
In contrast, SRV-3 Env expression in trans was sufficient to promote the release of the 
env-deleted SRV-3 virions in the presence of rhesus tetherin, suggesting that the SRV-3 
Env glycoprotein has anti-tetherin activity (Figure 3.1C).  
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Unlike the lentiviruses, the assembly of betaretroviruses require the presence of 
the envelope glycoproteins for efficient viral release.174 As such, I found it difficult to 
assess the effects of rhesus tetherin and human tetherin on the release of env-deleted 
SRV-3 virions in the absence of any envelope glycoprotein. Hence, this raises the 
possibility that the rescue of env-deleted SRV-3 virions might be the effect of a general 
enhancement of virion release by the SRV-3 envelope, and not due to its anti-tetherin 
function. To address the first possibility, we co-expressed the SRV-3 envelope in trans to 
test if the transient expression of SRV-3 envelope was enhancing the release of the env-
deleted SRV-3 virions in the absence of any tetherin orthologues. While expression of 
SRV-3 Env sometimes resulted in a small enhancement of release to controls, this was 
not sufficient to explain the significant differences in release between cells expressing 
human tetherin and cells expressing rhesus tetherin. Furthermore, co-expression of VSV-
G in trans failed to rescue the release of SRV-3∆env virus from either human or rhesus 
tetherin orthologues (Figure 3.1C), confirming that the efficient release in the presence of 
tetherin depends on the expression of a functional tetherin antagonist- either Vpu (in the 
case of human tetherin) or Nef or SRV-3 Env glycoprotein (in the case of rhesus 
tetherin).  
We also observed that the transient expression of SRV-3 envelope rescued a 
heterologous virus (SIVmac239∆nef∆env) from rhesus tetherin but not from human 
tetherin (Figure 3.2). These observations strongly suggest that- i) the expression of the 
SRV-3 envelope alone is sufficient to antagonize rhesus tetherin and does not require the 
presence of any other SRV-3 proteins and ii) unlike the FIV envelope glycoprotein, 
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which specifically rescues only FIV particles from tetherin, the anti-tetherin activity of 
SRV-3 envelope is not specific to SRV-3 virions.161 
Both HIV-1 Vpu and SIVmac Nef physically interact with their respective host 
tetherin orthologues.122,140 Our results from the co-immunoprecipitation assay suggest 
that the SRV-3 Env physically interacts with rhesus tetherin, and that the interaction 
involves the 14GDIWK18 residues in the rhesus tetherin cytoplasmic tail. However, it is 
still unclear whether some or all of these five residues within the 14GDIWK18 motif are 
critical for mediating the interaction between the SRV-3 envelope and rhesus tetherin.  
Interestingly, we found that the SRV-3 envelope glycoprotein exhibits anti-
tetherin activity against a diverse panel of tetherin orthologues, including various 
primate, dog and cat tetherin. While the 14GDIWK18 motif is not absolutely conserved 
among these tetherin proteins, the aspartate at position 15 is found in all the tetherin 
orthologues that we tested (except human tetherin). Deleting the aspartate at position 15 
or substituting it with an alanine reduced the susceptibility of rhesus tetherin to SRV-3 
envelope-mediated tetherin antagonism (Figure 3.11). A similar observation was also 
reported by Jia et al., regarding SIVmac Nef-mediated tetherin-antagonism.112 Thus, it 
may not be the primary sequence but rather a conserved secondary or tertiary structural 
element encompassing aspartate 15 that confers recognition by the SRV-3 envelope. 
Additionally, we observed that the envelope glycoproteins of several additional 
gammaretroviruses also exhibited patterns of tetherin-antagonism similar to SRV-3 Env 
(Figures 3.10 and 3.12). All these observations suggest that the gamma-type envelope 
glycoproteins are the second type of viral protein, after the primate lentiviral Nef 
proteins, that have converged to specifically target the same element in the cytoplasmic 
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tail of tetherin for tetherin-antagonism. This convergence further suggests that the region 
encompassing the 14GDIWK18 motif may have properties especially amenable to protein-
protein interactions. Therefore, it would be interesting to find out whether the interactions 
of tetherin with the gammaretroviral envelope and Nef protein involve similar 
intermolecular contacts. 
The convergence of at least two different viral proteins on the same target also 
highlights the difficulties of implicating specific viruses as past agents of selection. 
Previous studies have reported that the loss of the five residues (14GDIWK18) from the 
cytoplasmic tail of human tetherin confers resistance against Nef.89,175 This protective 
deletion is also present in the archaic humans namely the Neanderthals and Denisova, 
indicating that the deletion arose nearly 800,000 years ago.89 Compton et al., have 
suggested that the variation in this region of tetherin is the result of selective pressure 
exerted by previous encounters between ancestral humans and lentiviruses that probably 
encoded Nef-like tetherin antagonists.175 However, our results suggest that the selection 
of this protective deletion could also have been driven by an ancient virus with a gamma-
type envelope. Indeed, several of the viral Envs used in our study come from viruses that 
infect primate hosts. 
The tetherin antagonists of complex retroviruses such as HIV-1 Vpu and SIVmac 
Nef downregulate cell surface expression of human and rhesus tetherin respectively.112 
We found that the SRV-3 envelope also downmodulates rhesus tetherin and not human 
tetherin from the cell surface. However, it is still unclear whether SRV-3 envelope 
mediates degradation of rhesus tetherin after removing it from the virus budding sites. 
Thus, further studies are required to define the detailed mechanism of SRV-3 envelope-
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mediated tetherin-antagonism.  
Previously, a tyrosine-based motifs in the cytoplasmic tail of HIV-2 envelope and 
the EnvITM of the SIVmac∆nefP were shown to be critical for tetherin-antagonism.93,159 
The cytoplasmic tail of SRV-3 envelope harbors two such tyrosine-based motifs. Of these 
two motifs, the tyrosine at position 23 is important for envelope trafficking and for the 
incorporation of the envelope glycoproteins into the virions during viral assembly and 
budding.33,176 Additionally, a dileucine-based motif in the SRV-3 envelope cytoplasmic 
tail has been reported to mediate its anterograde transport.33 Our data from the site-
directed mutagenesis and alanine scanning mutagenesis indicate that the mutations in the 
SRV-3 envelope trafficking signals did not abrogate its ability to downregulate the cell-
surface rhesus tetherin expression (Figure 3.8); however, its ability to rescue virion 
release in the presence of rhesus tetherin was significantly reduced by the mutations 
(Figure 3.9). Indeed, reduction in the virion release due to the mutations in the SRV-3 
envelope trafficking motifs was observed in the presence as well as in the absence of 
tetherin (Figure 3.9). These observations corroborate previous findings by Song et al., 
who showed that the mutations in the tyrosine-based motif at position 23 affected the 
incorporation of envelope glycoproteins into the SRV-3 virions, and impaired virion 
assembly and release.176 Since the mutations in the di-leucine motif of the SRV-3 
envelope prevents the anterograde transport of the envelope glycoprotein,33 it not 
surprising that these mutations are also leading to a reduction in the virion release 
irrespective of the presence or absence of tetherin (Figure 3.9). These results also 
highlight the difficulty in mapping a tetherin-interacting domain in the SRV-3 Env; that 
is, mapping a binding site by mutagenesis is confounded by the pleiotropic effects of 
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mutations that may also have on trafficking, assembly and virion release. 
Overall, our data suggests that SRV-3 envelope-mediated tetherin antagonism is 
not dependent on the incorporation of the viral envelope glycoproteins into the virions; 
instead it indicates the possibility of a direct interaction between the SRV-3 envelope 
glycoprotein and rhesus tetherin within the secretory pathway preventing tetherin from 
reaching the cell surface. Hence, we speculate that the SRV-3 envelope might be 
resulting in the intracellular sequestration of de novo synthesized tetherins and preventing 
their anterograde transport. 
Our work reflects that the envelope glycoproteins of gammaretroviruses and the 
type-D betaretroviruses are potent tetherin antagonists and have evolved to actively evade 
tetherin-mediated restriction. Several other viral entry proteins have been implicated as 
tetherin antagonists. For instance, HIV-2 adapted to the deletion in the human tetherin by 
repurposing its envelope glycoprotein.93 Similarly, during in vivo passage SIVmac∆nefP 
also adapted to rhesus tetherin by repurposing its envelope glycoprotein.159 The entry 
proteins of Ebola virus (filovirus) and HERV-K (an endogenous retrovirus) have also 
been described as having anti-tetherin capacity in cell culture.100,163 To the extent that 
some or all of these observations reflect bona fide tetherin antagonists, they raise an 
intriguing question: Do the viral entry glycoproteins have properties that predispose them 
to evolving anti-tetherin activity?  
Similar to several other cell surface and secretory proteins, the viral envelope 
glycoproteins are synthesized in the RER and traffic through the secretory pathway. 
Therefore, the viral envelope glycoproteins are in a position to interact with other 
proteins within the RER and the secretory pathway. Many retroviral envelope 
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glycoproteins mediate receptor interference by either downmodulating or sequestering 
their cognate host cell receptors. Therefore, it is easy to imagine that adaptations in a 
viral entry protein that result in a direct physical interaction between the viral envelope 
glycoprotein and tetherin within the ER or the secretory pathway could also lead to the 
intracellular sequestration of newly synthesized tetherins by a mechanism analogous to 
receptor interference. Since the viral envelope glycoproteins and tetherins are both 
membrane-associated proteins and localize at the virion budding sites at the plasma 
membrane, this also suggests the possibility of an interaction between the two proteins at 
the cell surface resulting in the removal of tetherin from sites of active virion assembly. 
Hence, considering all these characteristics of the viral envelope glycoproteins, it is not 
surprising that in the absence of a dedicated tetherin antagonist, the simple retroviruses of 
the recombinant beta- and gammaretrovirus genera have adapted to evade tetherin-
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